0001425450-22-000051.txt : 20220506 0001425450-22-000051.hdr.sgml : 20220506 20220505162531 ACCESSION NUMBER: 0001425450-22-000051 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORTHOPEDIATRICS CORP CENTRAL INDEX KEY: 0001425450 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 261761833 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38242 FILM NUMBER: 22896742 BUSINESS ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 BUSINESS PHONE: 574-268-6379 MAIL ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 10-Q 1 kids-20220331.htm 10-Q kids-20220331
2022Q1FALSE0001425450--12-31http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://www.orthopediatrics.com/20220331#AssetsNoncurrentExcludingPropertyPlantAndEquipmenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://www.orthopediatrics.com/20220331#AssetsNoncurrentExcludingPropertyPlantAndEquipment00014254502022-01-012022-03-3100014254502022-05-03xbrli:shares00014254502022-03-31iso4217:USD00014254502021-12-31iso4217:USDxbrli:shares00014254502021-01-012021-03-310001425450us-gaap:CommonStockMember2021-12-310001425450us-gaap:AdditionalPaidInCapitalMember2021-12-310001425450us-gaap:RetainedEarningsMember2021-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001425450us-gaap:RetainedEarningsMember2022-01-012022-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001425450us-gaap:CommonStockMember2022-01-012022-03-310001425450us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001425450us-gaap:CommonStockMember2022-03-310001425450us-gaap:AdditionalPaidInCapitalMember2022-03-310001425450us-gaap:RetainedEarningsMember2022-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001425450us-gaap:CommonStockMember2020-12-310001425450us-gaap:AdditionalPaidInCapitalMember2020-12-310001425450us-gaap:RetainedEarningsMember2020-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100014254502020-12-310001425450us-gaap:RetainedEarningsMember2021-01-012021-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001425450us-gaap:CommonStockMember2021-01-012021-03-310001425450us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001425450us-gaap:CommonStockMember2021-03-310001425450us-gaap:AdditionalPaidInCapitalMember2021-03-310001425450us-gaap:RetainedEarningsMember2021-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100014254502021-03-31kids:children0001425450country:US2022-03-3100014254502019-12-31iso4217:EUR0001425450us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2022-01-012022-03-310001425450us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2022-01-012022-03-310001425450us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2022-01-012022-03-310001425450us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2022-01-012022-03-310001425450us-gaap:ComputerEquipmentMembersrt:MinimumMember2022-01-012022-03-310001425450us-gaap:ComputerEquipmentMembersrt:MaximumMember2022-01-012022-03-310001425450us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-01-012022-03-310001425450us-gaap:OfficeEquipmentMembersrt:MinimumMember2022-01-012022-03-310001425450us-gaap:OfficeEquipmentMembersrt:MaximumMember2022-01-012022-03-310001425450us-gaap:TechnologyEquipmentMember2022-01-012022-03-310001425450kids:SampleInventoryMember2022-01-012022-03-310001425450srt:MinimumMember2022-01-012022-03-310001425450srt:MaximumMember2022-01-012022-03-31kids:reportingUnit0001425450kids:A2007EquityIncentivePlanMember2017-09-300001425450kids:New2017EquityIncentivePlanMember2022-03-310001425450us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-03-310001425450us-gaap:RestrictedStockMember2022-01-012022-03-310001425450us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockMember2022-01-012022-03-310001425450us-gaap:RestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-01-012022-03-310001425450us-gaap:PatentsMember2022-01-012022-03-310001425450us-gaap:PatentsMember2022-03-310001425450us-gaap:IntellectualPropertyMember2022-01-012022-03-310001425450us-gaap:IntellectualPropertyMember2022-03-310001425450us-gaap:LicensingAgreementsMember2022-01-012022-03-310001425450us-gaap:LicensingAgreementsMember2022-03-310001425450us-gaap:PatentsMember2021-01-012021-12-310001425450us-gaap:PatentsMember2021-12-310001425450us-gaap:IntellectualPropertyMember2021-01-012021-12-310001425450us-gaap:IntellectualPropertyMember2021-12-310001425450us-gaap:LicensingAgreementsMember2021-01-012021-12-310001425450us-gaap:LicensingAgreementsMember2021-12-310001425450us-gaap:TrademarksMember2022-03-310001425450us-gaap:TrademarksMember2021-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-03-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-03-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-03-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberkids:ContingentConsiderationLiabilityMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberkids:ContingentConsiderationLiabilityMember2022-01-012022-03-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberkids:ContingentConsiderationLiabilityMember2022-03-310001425450us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MeasurementInputDiscountRateMember2022-03-31xbrli:pure0001425450us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001425450us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001425450us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-03-310001425450us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310001425450us-gaap:MortgagesMember2022-03-310001425450us-gaap:MortgagesMember2021-12-310001425450us-gaap:RevolvingCreditFacilityMember2021-12-310001425450kids:ThirdAmendedLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberkids:SecuredOvernightFinancingRateMember2021-12-312021-12-310001425450kids:ThirdAmendedLoanAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-12-310001425450kids:SecondAmendedLoanAgreementMemberus-gaap:RevolvingCreditFacilityMember2020-08-042020-08-040001425450kids:SecondAmendedLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-08-042020-08-040001425450kids:SecondAmendedLoanAgreementMemberus-gaap:RevolvingCreditFacilityMember2020-08-040001425450us-gaap:MortgagesMember2022-01-012022-03-310001425450us-gaap:NotesPayableOtherPayablesMember2022-01-012022-03-310001425450us-gaap:NotesPayableOtherPayablesMember2021-01-012021-03-310001425450us-gaap:DomesticCountryMember2021-12-310001425450us-gaap:StateAndLocalJurisdictionMember2021-12-3100014254502014-05-3000014254502018-12-110001425450us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001425450us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001425450us-gaap:EmployeeStockOptionMember2021-12-310001425450us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001425450us-gaap:EmployeeStockOptionMember2022-03-310001425450us-gaap:RestrictedStockMember2021-12-310001425450us-gaap:RestrictedStockMember2021-01-012021-12-310001425450us-gaap:RestrictedStockMember2022-03-310001425450us-gaap:RestrictedStockMember2021-01-012021-03-310001425450us-gaap:RestrictedStockMember2022-01-012022-03-310001425450us-gaap:RestrictedStockMember2021-01-012021-03-310001425450us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001425450us-gaap:EmployeeStockOptionMember2021-01-012021-03-31kids:segment0001425450country:US2022-01-012022-03-310001425450country:US2021-01-012021-03-310001425450us-gaap:NonUsMember2022-01-012022-03-310001425450us-gaap:NonUsMember2021-01-012021-03-310001425450kids:TraumaAndDeformityMember2022-01-012022-03-310001425450kids:TraumaAndDeformityMember2021-01-012021-03-310001425450kids:SpineMember2022-01-012022-03-310001425450kids:SpineMember2021-01-012021-03-310001425450kids:SportsMedicineAndOtherMember2022-01-012022-03-310001425450kids:SportsMedicineAndOtherMember2021-01-012021-03-310001425450srt:AffiliatedEntityMember2022-01-012022-03-31kids:supplier0001425450kids:StructureMedicalLLCMembersrt:AffiliatedEntityMember2022-01-012022-03-310001425450kids:StructureMedicalLLCMembersrt:AffiliatedEntityMember2021-01-012021-03-310001425450us-gaap:DiscontinuedOperationsDisposedOfBySaleMembersrt:AffiliatedEntityMember2019-12-310001425450kids:VilexMembersrt:AffiliatedEntityMember2022-01-012022-03-310001425450kids:VilexMembersrt:AffiliatedEntityMember2021-01-012021-03-310001425450kids:VilexAndOrthexMember2019-06-012019-06-300001425450kids:TeamNoteBMemberkids:SquadronMembersrt:AffiliatedEntityMember2019-12-312019-12-310001425450us-gaap:LicensingAgreementsMemberkids:FireflyTechnologyMember2021-07-202021-07-200001425450us-gaap:LicensingAgreementsMemberkids:FireflyTechnologyMember2022-01-012022-03-310001425450us-gaap:LicensingAgreementsMemberkids:FireflyTechnologyMember2021-01-012021-03-310001425450us-gaap:SubsequentEventMemberkids:MitchellDesignsIncMember2022-04-012022-04-010001425450us-gaap:SubsequentEventMemberkids:MitchellDesignsIncMember2022-04-010001425450us-gaap:SubsequentEventMemberkids:ApiFixLtdMember2022-04-012022-04-010001425450us-gaap:SubsequentEventMemberkids:ApiFixLtdMember2022-04-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-38242
OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)
Delaware
26-1761833
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
2850 Frontier Drive
Warsaw, IN 46582
(574) 268-6379
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00025 par value per shareKIDSNasdaq Global Market
________________________________________________________________________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐    No ☒

As of May 3, 2022, the registrant had 20,229,901 outstanding shares of common stock, $0.00025 par value per share.




OrthoPediatrics Corp.
Form 10-Q
For the Quarterly Period Ended March 31, 2022

TABLE OF CONTENTS
Page No.
PART I. FINANCIAL INFORMATION
Item 1
Item 2
Item 3
Item 4
PART II. OTHER INFORMATION
Item 1
Item 1A
Item 2
Item 3
Item 4
Item 5
Item 6







NOTE REGARDING FORWARD-LOOKING STATEMENTS

All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. You can often identify forward-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "target," "ongoing," "plan," "potential," "predict," "project," "should," "will" or "would," or the negative of these terms or other terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of the COVID-19 pandemic, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to:

•our ability to achieve or sustain profitability in the future;

•our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations;

•our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively;

•our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability;

•our ability to comply with extensive government regulation and oversight both in the United States and abroad;

•our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and

•our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others;

We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 3, 2022 and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report.
3

PART I. FINANCIAL INFORMATION

ITEM 1.        FINANCIAL STATEMENTS
ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In Thousands, Except Share Data)
March 31, 2022December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents$17,957 $7,641 
Restricted cash1,363 1,365 
Short term investments27,068 45,902 
Accounts receivable - trade, less allowance for doubtful accounts of $357 and $347, respectively
17,911 17,942 
Inventories, net64,077 57,569 
Prepaid expenses and other current assets3,048 3,229 
Total current assets131,424 133,648 
Property and equipment, net31,068 28,515 
Other assets:
Amortizable intangible assets, net53,476 55,494 
Goodwill70,987 72,349 
Other intangible assets14,040 14,268 
Total other assets138,503 142,111 
Total assets$300,995 $304,274 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade$14,578 $9,325 
Accrued compensation and benefits4,433 5,351 
Current portion of long-term debt with affiliate139 137 
Current portion of acquisition installment payable12,934 12,862 
Other current liabilities2,249 2,040 
Total current liabilities34,333 29,715 
Long-term liabilities:
Long-term debt with affiliate, net of current portion872 907 
Acquisition installment payable, net of current portion14,690 14,309 
Contingent consideration31,480 28,910 
Deferred income taxes4,335 4,771 
Other long-term liabilities241 293 
Total long-term liabilities51,618 49,190 
Total liabilities85,951 78,905 
Stockholders' equity:
Common stock, $0.00025 par value; 50,000,000 shares authorized; 19,821,298 shares and 19,677,214 shares issued as of March 31, 2022 (unaudited) and December 31, 2021, respectively
5 5 
Additional paid-in capital396,425 394,899 
Accumulated deficit(187,126)(178,026)
Accumulated other comprehensive income5,740 8,491 
Total stockholders' equity215,044 225,369 
Total liabilities and stockholders' equity$300,995 $304,274 

See notes to condensed consolidated financial statements.
4

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In Thousands, Except Share and Per Share Data)
Three Months Ended March 31,
20222021
Net revenue$23,417 $21,462 
Cost of revenue4,851 5,137 
Gross profit18,566 16,325 
Operating expenses:
Sales and marketing9,758 8,949 
General and administrative13,167 12,041 
Research and development2,027 1,308 
Total operating expenses24,952 22,298 
Operating loss(6,386)(5,973)
Other expenses:
Interest expense, net566 728 
Fair value adjustment of contingent consideration2,570 4,150 
Other income(105)(160)
Total other expenses3,031 4,718 
Loss before income taxes$(9,417)$(10,691)
Provision for income taxes (benefit)(317)(312)
Net loss$(9,100)$(10,379)
Weighted average common stock - basic and diluted19,366,911 19,200,231 
Net loss per share - basic and diluted$(0.47)$(0.54)

See notes to condensed consolidated financial statements.
5

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(In Thousands)
Three Months Ended March 31,
20222021
Net loss$(9,100)$(10,379)
Other comprehensive loss:
Foreign currency translation adjustment(2,198)(3,499)
Unrealized loss on short-term investments(553)(123)
Other comprehensive loss, net of tax(2,751)(3,622)
Comprehensive loss$(11,851)$(14,001)

See notes to condensed consolidated financial statements.
6

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Share Data)
Three Months Ended March 31, 2022
Accumulated
AdditionalOtherTotal
Common StockPaid-inAccumulatedComprehensiveStockholders'
SharesValueCapitalDeficitIncome (Loss)Equity
Balance at January 1, 202219,677,214 $5 $394,899 $(178,026)$8,491 $225,369 
Net loss— — — (9,100)— (9,100)
Other comprehensive loss— — — — (2,751)(2,751)
Restricted stock144,084 — 1,526 — — 1,526 
Balance at March 31, 202219,821,298 $5 $396,425 $(187,126)$5,740 $215,044 

7

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Share Data)
Three Months Ended March 31, 2021
Accumulated
AdditionalOtherTotal
Common StockPaid-inAccumulatedComprehensiveStockholders'
SharesValueCapitalDeficitIncome (Loss)Equity
Balance at January 1, 202119,560,291 $5 $388,622 $(161,766)$7,907 $234,768 
Net loss— — — (10,379)— (10,379)
Other comprehensive loss— — — — (3,622)(3,622)
Stock option exercise2,010 — 62 — — 62 
Restricted stock97,111 — 1,316 — — 1,316 
Balance at March 31, 202119,659,412 $5 $390,000 $(172,145)$4,285 $222,145 

See notes to condensed consolidated financial statements.
8

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In Thousands)
Three Months Ended
March 31,
20222021
OPERATING ACTIVITIES
Net loss$(9,100)$(10,379)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization2,961 2,539 
Stock-based compensation1,526 1,316 
Fair value adjustment of contingent consideration2,570 4,150 
Acquisition installment payable453 644 
Deferred income taxes(317)(312)
Changes in certain current assets and liabilities:
Accounts receivable - trade2 653 
Inventories(6,750)(2,508)
Prepaid expenses and other current assets112 708 
Accounts payable - trade5,258 2,058 
Accrued legal settlements— (1,092)
Accrued expenses and other liabilities(690)446 
Other(222)(138)
Net cash used in operating activities(4,197)(1,915)
INVESTING ACTIVITIES
Sale of short-term marketable securities18,500 — 
Purchases of licenses— (2,858)
Purchases of property and equipment(4,197)(2,749)
Net cash provided by (used in) investing activities14,303 (5,607)
FINANCING ACTIVITIES
Proceeds from exercise of stock options— 62 
Payments on mortgage notes(33)(32)
Net cash (used in) provided by financing activities(33)30 
Effect of exchange rate changes on cash241 155 
NET (DECREASE) INCREASE IN CASH10,314 (7,337)
Cash and restricted cash, beginning of year$9,006 $30,132 
Cash and restricted cash, end of period$19,320 $22,795 
SUPPLEMENTAL DISCLOSURES
Cash paid for interest$13 $15 
Transfer of instruments from property and equipment to inventory$(54)$57 
See notes to condensed consolidated financial statements.
9

ORTHOPEDIATRICS CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(Dollars In Thousands, Except Share and Per Share data)
NOTE 1 – BUSINESS

OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSETM Spine, BandLocTM, Pediatric Nailing Platform | Femur, Orthex, QuickPackTM and ApiFix® Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation.

We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 243,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300 opportunity globally, including over $1,500 in the United States.

Our largest investor is Squadron, a private investment firm based in Granby, Connecticut.

A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. As a result of the pandemic, we have experienced significant business disruption. For example, in preparation for COVID-19-related hospitalizations, various governments, governmental agencies and hospital administrators required certain hospitals to postpone some elective procedures. As a majority of our products are utilized in elective surgeries or procedures, the deferrals of such surgeries and procedures have had, and may continue to have, a significant negative impact on our business and results of operations. Despite the impact COVID-19 has had on our business, we continued to invest in research and development, invest in our people, and take steps to position ourselves for long-term success. We continue to train and educate our sales team and our surgeons on our products. We have continued to focus on developing innovative solutions, acquired multiple enabling technologies, invested in both new and existing partnerships and continued to deploy additional consigned instrument and implant sets in furtherance of our strategy. The extent to which COVID-19 may continue to negatively impact the Company's consolidated financial position, results of operations or cash flows is uncertain and will be closely monitored.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V.,
10

Orthex, LLC, Telos Partners, LLC and ApiFix, Ltd. (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2022 and 2021 and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $187,126 and $178,026 as of March 31, 2022 and December 31, 2021, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short term investments, at March 31, 2022 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months.

Use of Estimates

Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.

Foreign Currency Transactions

We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense.

Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland,
11

Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss.

Revenue from Contracts with Customers

In accordance with ASC 606, "Revenue from Contracts with Customers," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement.
Revenue Recognition – International

Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns.
Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when title passes upon shipment. Pricing for each customer is dictated by a unique pricing agreement.

Cash, Cash Equivalents and Short Term Investments

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value.

The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the
12

next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations.

Restricted Cash

In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the March 31, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 12 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 100 Euro at its Netherlands entity for potential Italian tenders.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.

The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.

Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.   

The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment
13

payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 4 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis.

Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.

In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.

Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.

14

Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years

Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses, including Band-Lok, the value of internally developed software, customer relationships, and non-competition agreements related to the acquisition of Orthex, and customer relationships and non-competition agreements related to the acquisitions of Telos and ApiFix. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period.

Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges were recorded in any of the periods presented.

Goodwill and Other Intangible Assets

Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No impairment charges were recorded in any of the periods presented.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof.

We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented.




15

Acquisition Payable and Contingent Consideration

Upon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. The amount of expense related to acquisition installment payables recorded in interest expense, net for the three months ended March 31, 2022 and March 31, 2021 were $453 and $644, respectively. The fair value adjustments of contingent consideration for the three months ended March 31, 2022 and March 31, 2021 were expense adjustments of $2,570 and $4,150, respectively.

Cost of Revenue

Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.

Advertising Costs

Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.

Research and Development Costs

Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.

Stock-Based Compensation

Prior to our Initial Public Offering ("IPO") in October 2017, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award.

16

Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.

Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.

Litigation and Contingencies

Accruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period.

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance.

17

We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease.

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.

“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company.

Recent Accounting Pronouncements

In October 2021, the FASB issued ASU No. 2021-08 "Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
18

years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.

In May 2021, the FASB issued ASU No. 2021-04 "Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments". The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures.


NOTE 3 - GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill for the three months ended March 31, 2022 were as follows:
Total
Goodwill at January 1, 2022$72,349 
Foreign currency translation impact(1,362)
Goodwill at March 31, 2022
$70,987 

19

Intangible Assets

As of March 31, 2022, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.5 years$43,656 $(6,287)$37,369 
Intellectual Property9.8 years9,834 (1,584)8,250 
License Agreements5.2 years10,674 (2,817)7,857 
Total amortizable assets$64,164 $(10,688)$53,476 

As of December 31, 2021, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.7 years$44,493 $(5,664)$38,829 
Intellectual Property10.1 years9,847 (1408)8,439 
License Agreements5.5 years10,674 (2,448)8,226 
Total amortizable assets$65,014 $(9,520)$55,494 

Licenses are tied to product launches and do not begin amortizing until the product is launched to the market.

Trademarks are non-amortizing intangible assets which were $14,040 and $14,268 as of March 31, 2022 and December 31, 2021, respectively. Trademarks are recorded in Other Intangible assets on the condensed consolidated balance sheets. The change in balance during the three months ended March 31, 2022 was the result of foreign currency translation of the ApiFix trademark.


NOTE 4 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.

The following table summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021.
20

March 31, 2022
Level 1Level 2Level 3Total
Financial Assets
Short term investments
Corporate Bonds$13,776 $— $— $13,776 
Treasury Bonds$7,445 $— $— $7,445 
Asset Backed Securities$— $5,261 $— $5,261 
Other$586 $— $— $586 
Financial Liabilities
Contingent Consideration$— $— $31,480 $31,480 
December 31, 2021
Level 1Level 2Level 3Total
Financial Assets
Short term investments
Corporate Bonds$22,476 $— $— $22,476 
Treasury Bonds$14,317 $— $— $14,317 
Asset Backed Securities$— $8,272 $— $8,272 
Other$837 $— $— $837 
Financial Liabilities
Contingent Consideration$— $— $28,910 $28,910 

The Company's level 1 assets consist of cash equivalents which are generally comprised of short-term, liquid investments with original maturity of three months or less at inception and other short term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months.

The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date using an option pricing model and a Monte Carlo simulation based on forecasted annual revenue, expected volatility and discount rates. The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement. The adjustments in the fair value of the contingent consideration payments included expense adjustment of $2,570 and $4,150 for the three month periods ended March 31, 2022 and March 31, 2021, respectively, in other expenses on the condensed consolidated statements of operations.

The following table summarizes the change in fair value of Level 3 instruments in 2022:
Total
Balance at January 1, 2022
$28,910 
Change in fair value of contingent consideration2,570 
Balance at March 31, 2022
$31,480 
21


The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of March 31, 2022 and December 31, 2021:
March 31, 2022December 31, 2021
Valuation techniquesDiscounted cash flow, Monte Carlo
Present value discount rate(1)
19.3 %18.4 %
Volatility factor46.5 %50.3 %
Expected years2.1 years2.4 years

(1) The present value discount rate includes estimated risk premium.

The estimated fair value reflects assumptions made by management as of March 31, 2022; however, the actual amount ultimately paid could be higher or lower than the fair value of the remaining contingent consideration.


NOTE 5 - DEBT AND CREDIT ARRANGEMENTS

Long-term debt consisted of the following:
March 31, 2022December 31, 2021
Mortgage payable to affiliate$1,011 $1,044 
Less: current maturities139 137 
Long-term debt with affiliate, net of current maturities$872 $907 

Effective December 31, 2021, the Company entered into a Third Amendment (the "Third Amendment") to its Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC, or Squadron (as so amended, the “Loan Agreement”). The Loan Agreement provides a $25,000 revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears. Prior to the Third Amendment, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. While the Loan Agreement previously provided for certain term loans, there are no longer any outstanding term loan obligations.

Borrowings under the revolving credit facility are made under a First Amended and Restated Revolving Note, dated August 4, 2020 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions.
22


In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At March 31, 2022 the mortgage balance was $1,011 of which current principal of $139 was included in the current portion of long-term debt. As of December 31, 2021, the mortgage balance was $1,044 of which current principal due of $137 was included in the current portion of long-term debt.

The aggregate interest expense relating to the notes payable to Squadron and the mortgage note payable to Tawani was $13 and $15 for the three months ended March 31, 2022 and 2021, respectively.

NOTE 6 - INCOME TAXES

The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss).

For the three months ended March 31, 2022, the income tax benefit was $317 compared to $312 for the three months ended March 31, 2021. Our effective income tax rate was 3.4% and 2.9% for the three months ended March 31, 2022 and 2021, respectively.

The deferred tax assets were fully offset by a valuation allowance at March 31, 2022 and December 31, 2021, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix. The company has recorded a tax benefit during the period ended March 31, 2022 for losses generated in the foreign jurisdiction. As of December 31, 2021, we had available federal, state and foreign tax loss carryforwards of $114,008, $73,997 and $22,671, respectively. We had available federal tax credits of $176. Net operating losses generated prior to December 31, 2017 will begin to expire in 2028. Federal net operating losses generated after January 1, 2018 will have an indefinite carryforward period. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $23,920 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062. A second ownership change under Section 382 was deemed to occur on December 11, 2018. The estimated annual limitation is $9,736, which is increased by $22,430 annually over the first five years as a result of an unrealized built in gain. NOLs sustained prior to May 30, 2014 will still be constrained by the lower limitation.

Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended March 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth.

NOTE 7 - STOCKHOLDERS’ EQUITY

Stock Options

The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.

23

Our stock option activity and related information are summarized as follows:
Weighted-AverageContractual Terms
OptionsExercise Price(in Years)
Outstanding at January 1, 20226,638 $30.97 1.3
Outstanding at March 31, 2022
6,638 $30.97 1.1

Options generally include a time-based vesting schedule permitting the options to vest ratably over three years. At March 31, 2022 and December 31, 2021, all options were fully vested.

There was no stock-based compensation expense on stock options for the three months ended March 31, 2022 and 2021, respectively.


Restricted Stock

Our restricted stock activity and related information are summarized as follows:
Weighted-Average
Remaining
RestrictedContractual Terms
Stock(in Years)
Outstanding at January 1, 2022368,446 1.1
Granted146,425 
Forfeited(2,341)
Vested(120,656)
Outstanding at March 31, 2022
391,874 1.9
Restricted stock exercisable at March 31, 2022
— 

At March 31, 2022, there was $12,443 of unrecognized compensation expense remaining related to our service-based restricted stock awards. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 1.9 years or earlier upon an elimination of the restriction period as a result of a change in control event.

Stock-based compensation expense on restricted stock amounted to $1,526 and $1,440 for the three months ended March 31, 2022 and 2021, respectively. The increase in the stock compensation for the three months ended March 31, 2022 is primarily due to increase in plan participants as we continue to hire employees to support the continued expansion of our business.

NOTE 8 – NET LOSS PER SHARE

The following is a reconciliation of basic and diluted net loss per share:
Three Months Ended
March 31,
20222021
Net loss$(9,100)$(10,379)
Weighted average number of shares - basic and diluted19,366,911 19,200,231 
Net loss per share - basic and diluted$(0.47)$(0.54)

Our basic and diluted net loss per share is computed using the two-class method.  The two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or
24

losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. 

Because we have incurred a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share. The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented:
Three Months Ended March 31,
20222021
Restricted stock391,874 389,098 
Stock options6,638 10,792 
Total shares398,512 399,890 

NOTE 9 – BUSINESS SEGMENT

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No customers accounted for more than 10% of total product sales for the three months ended March 31, 2022 or 2021. No customer accounted for more than 10% of consolidated accounts receivable as of March 31, 2022 and December 31, 2021.

Product sales by source were as follows:
Three Months Ended March 31,
Product sales by geographic location:20222021
U.S.$18,188 $16,839 
International5,229 4,623 
Total$23,417 $21,462 
Three Months Ended March 31,
Product sales by category:20222021
Trauma and deformity$16,516 $14,552 
Scoliosis5,983 5,951 
Sports medicine/other918 959 
Total$23,417 $21,462 

25

No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three months ended March 31, 2022 and 2021.

NOTE 10 - RELATED PARTY TRANSACTIONS
In addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $316 and $72 for the three months ended March 31, 2022 and 2021, respectively.
On December 31, 2019, the Company divested Vilex for $25,000 to an affiliate of Squadron. In conjunction with the divestiture, the Company also entered into an exclusive perpetual license agreement to permit the purchasers of Vilex the ability to access intellectual property and sell products using the external fixation technology of Orthex, LLC to non-pediatric accounts. We had sales and payments related to inventory purchases to Squadron's affiliate, now known as Vilex, LLC, of $8 and $25, respectively, for the three months ended March 31, 2022. We had sales and payments related to inventory purchases to Vilex, LLC of $87 and $189, respectively, for the three months ended March 31, 2021.

NOTE 11 - EMPLOYEE BENEFIT PLAN

We have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary.

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Leases

As of March 31, 2022, the Company has recorded a lease liability of $241 and corresponding right-of-use-asset of $243 on its condensed consolidated balance sheet.

Legal Proceedings

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.

IMED Surgical - Software Ownership Dispute

On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron Capital, LLC (“Squadron”), and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company (the “Plaintiff”), in Broward County, Florida Circuit Court. In the lawsuit, the Plaintiff claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).

26

In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point & Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent. According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with the Plaintiff.

The Plaintiff, among other things, requests that the defendants be ordered to convey and assign to Plaintiff all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants.

On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent the Plaintiff desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, the Plaintiff initiated an arbitration proceeding. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to the Plaintiff before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order.

Although we believe the IMED lawsuit is without merit and will vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.


Wishbone Medical, Inc. – Patent Infringement Litigation

On October 30, 2020, OrthoPediatrics, along with its wholly-owned subsidiary, Orthex, LLC, filed a lawsuit in federal district court (N.D. Indiana, South Bend Division, Case No. 3:20-cv-00929) against Wishbone Medical, Inc. and Nick A. Deeter (collectively “Wishbone”), claiming infringement of ’377 Patent, unfair competition, false advertising, breach of contract, defamation per se, tortious interference with contractual relationships, and tortious interference with prospective contractual relationships. In early January 2021, OrthoPediatrics amended its lawsuit by adding a declaratory judgment claim of infringement of the ‘377 Patent against Wishbone.

Thereafter, in January 2021, Wishbone filed a motion to dismiss all OrthoPediatrics’ causes of action. In late August 2021, the Court denied Wishbone's motion to dismiss with respect to OrthoPediatrics’ infringement and breach of contract claims and dismissed OrthoPediatrics' remaining causes of action. In late September 2021, Wishbone filed its answer and counterclaims, in part, seeking declaratory judgment of non-infringement and invalidity of the ‘377 Patent, and alleging OrthoPediatrics patent infringement claim(s) against Wishbone was made in bad faith. In mid-October 2021, OrthoPediatrics filed its answer to Wishbone’s counterclaims, denying all of them. Although we believe Wishbone’s counterclaims are without merit and will vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have an adverse effect on our business, operating results and financial condition.

27

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

Purchase Obligations and Performance Requirements

As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASHTM Navigation platform, the Company has agreed to a minimum purchase commitment for the first twelve months of that agreement. As of March 31, 2022, the remaining purchase commitment under the agreement was $1,900.

On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three months ended March 31, 2022, the Company recorded an expense of $101 based on current estimates. No expense was recorded for the three months ended March 31, 2021.

Royalties

As of March 31, 2022, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales.

We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of March 31, 2022, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.

NOTE 13 – SUBSEQUENT EVENTS

MD Orthopaedics Acquisition

On April 1, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with OrthoPediatrics Iowa Holdco, Inc., a Delaware corporation and newly-formed wholly-owned subsidiary of the Company (“Merger Sub”), Mitchell Designs, Inc. (“Designs”), an Iowa corporation and the sole shareholder of MD Orthopaedics, Inc., also an Iowa corporation (“MD Ortho”) and John Mitchell, the sole shareholder of Designs (“Mitchell”). MD Ortho has developed and manufactures a portfolio of orthopedic clubfoot products.

Pursuant to the Merger Agreement, Designs merged with and into Merger Sub effective April 1, 2022. Under the terms of the Merger Agreement, the Company paid to Mitchell consideration of (a) $8,200 in cash, and (b) 173,241 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $9,707 (based on the April 1, 2022 closing share price of $56.03).

ApiFix Acquisition Installment Payment

On April 1, 2022, the second-year anniversary of the acquisition of ApiFix, the Company paid $3,233 in cash and issued 185,811 shares of the Company's common stock, representing $10,411 of fair value (based on the April 1, 2022 closing share price of $56.03), to fulfill its installment obligation to ApiFix. This was the first installment payment paid since the acquisition.

28

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the condensed consolidated financial statements and related notes thereto contained elsewhere in this quarterly report, as well as the information under "Note Regarding Forward-Looking Statements."

The description of our business included in this quarterly report is summary in nature and only includes material developments that have occurred since the latest full description. The full description of the history and general development of our business is included in "Item 1. Description of Business" section of the Company's Annual Report on Form 10-K filed with the SEC on March 3, 2022, which section is incorporated herein by reference.

Overview

We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3.3 billion opportunity globally, including over $1.5 billion in the United States.

We sell implants and instruments to our customers for use by pediatric orthopedic surgeons to treat orthopedic conditions in children. We provide our implants in sets that consist of a range of implant sizes and include the instruments necessary to perform the surgical procedure. In the United States and a few selected international markets, our customers typically expect us to have full sets of implants and instruments on site at each hospital but do not purchase the implants until they are used in surgery. Accordingly, we must make an up-front investment in inventory of consigned implants and instruments before we can generate revenue from a particular hospital and we maintain substantial levels of inventory at any given time. In the international markets where we sell to stocking distributors, we transfer control of our products to the distributor when title passes upon shipment.

We currently market 37 surgical systems that serve three of the largest categories within the pediatric orthopedic market: (i) trauma and deformity, (ii) scoliosis and (iii) sports medicine/other. We rely on a broad network of third parties to manufacture the components of our products, which we then inspect and package. We believe our innovative products promote improved surgical accuracy, increase consistency of outcomes and enhance surgeon confidence in achieving high standards of care. In the future, we expect to expand our product offering within these categories, as well as to address additional categories of the pediatric orthopedic market.

The majority of our revenue has been generated in the United States, where we sell our products through a network of 40 independent sales agencies employing more than 188 sales representatives specifically focused on pediatrics. These independent sales agents are trained by us, distribute our products and are compensated through sales-based commissions and performance bonuses. We do not sell our products through or participate in physician-owned distributorships, or PODs.

We market and sell our products internationally in 45 countries, through independent stocking distributors and sales agencies. Our independent distributors manage the billing relationship with each hospital in their respective territories and are responsible for servicing the product needs of their surgeon customers. In 2017, we began to supplement our international stocking distributors with sales agencies using direct sales programs in the United Kingdom, Ireland, Australia and New Zealand where we sell directly to the
29

hospitals. We began selling direct to Canada in September 2018, Belgium and the Netherlands in January 2019, Italy in March 2020 and Germany, Switzerland and Austria in January 2021. Additionally, in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. In these markets, we work through sales agencies that are paid a commission, similar to our U.S. sales model. We expect these arrangements to generate an increase in revenue and gross margin.

We believe there are significant opportunities for us to strengthen our position in U.S. and international markets by increasing investments in consigned implant and instrument sets, strengthening our global sales and distribution infrastructure and expanding our product offering. For example, on April 1, 2022, the Company acquired MD Orthopaedics, Inc., a developer and manufacturer of a portfolio of orthopedic clubfoot products. The consideration paid by the Company included (a) $8.2 million in cash, and (b) 173,241 shares of its common stock, $0.00025 par value per share, representing approximately $9.7 million (based on the April 1, 2022 closing share price of $56.03).

Environmental, Social and Governance ("ESG") Activities

OrthoPediatrics was founded on the cause of impacting the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 243,000 children. We believe we should continue to expand our social efforts while minimizing our impact to the environment and ensuring corporate governance. In 2021, we created an internal ESG team, which reports directly to our Board’s Governance and Nominating Committee, to identify ESG topics for disclosure by assessing both the impact on our business and the importance to our stakeholders.

We encourage you to review our ESG page under the "About" section of our corporate website for more detailed information regarding our ESG efforts and current initiatives. On our website, among other information, are the following highlights:

•OrthoPediatrics cares about our environmental impact while working in a highly regulated industry and we are certified according to ISO 13485.

•The Company and its associates regularly participate in philanthropic causes important to our local communities. We also partner with charitable organizations that provide pediatric orthopedic care around the world. In 2020 we were named as "Corporate Partner of the Year" by the World Pediatric Project - with whom we work to provide access to medical care for children in developing countries.

•We are committed to fostering an environment that is respectful, compassionate, and inclusive of everyone in our community.

•The Board of Directors understands the value of diversity and will increase the diversity of the Board over the next 18 months. The Governance and Nominating Committee engaged a global recruiting firm to assist in adding two diverse Board candidates.

We believe effectively managing our priorities, as well as increasing our transparency related to ESG programs, will help create long-term value for our stakeholders. We expect to increase our disclosures and communicate our ESG efforts in future SEC filings.

Nothing on our website shall be deemed part of or incorporated by reference into this Quarterly Report on Form 10-Q.



Impact of COVID-19 on our Business
30


As a result of the COVID-19 pandemic (“COVID-19” or the “pandemic”), we have experienced significant business disruption. For example, in order to meet the demand for COVID-19-related hospitalizations, various governments, governmental agencies and hospital administrators required certain hospitals to postpone some elective procedures. As a majority of our products are utilized in elective surgeries or procedures, the deferrals of such surgeries and procedures have had, and may continue to have, a significant negative impact on our business and results of operations. We encourage the readers of this document to read our risk factors in their entirety contained in Item 1A “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 3, 2022 and in other reports filed with the SEC that discuss the risks and factors that may affect our business.

Despite the impact COVID-19 has had on our business, we continue to invest in research and development, invest in our people, and take steps to position ourselves for long-term success.

Health and Safety

From the earliest signs of the outbreak, we have taken proactive, aggressive action to protect the health and safety of our employees, customers, partners and suppliers. We enacted rigorous safety measures in all applicable locations, including implementing social distancing protocols, requiring working from home for those employees that do not need to be physically present on the warehouse floor, suspending travel, extensively and frequently disinfecting our workspaces and providing masks to those employees who must be physically present. We will continue to utilize some or all of these measures until we determine that the COVID-19 pandemic is adequately contained for purposes of our business. We may also take further actions as government authorities require or recommend or as we determine to be in the best interests of our employees, customers, partners and suppliers.

Supply

We have not yet experienced any significant impacts or interruptions to our supply chain as a result of the COVID-19 pandemic. To mitigate the risk of any potential supply interruptions from the COVID-19 pandemic, we chose to increase certain inventory levels during the quarter. We may decide to take similar actions going forward. Additionally, restrictions or disruptions of transportation, such as reduced availability of air transport, port closures and increased border controls or closures, may result in higher costs and delays.

Demand

The outbreak has significantly increased economic and demand uncertainty. We anticipate that the current outbreak or continued spread of COVID-19, and the actions taken by governmental authorities and other third parties to contain the virus, may cause a global economic slowdown, and it is possible that it could cause a global recession. In the event of a recession, demand for our products would decline and our business would be adversely effected. We have experienced a reduction in revenue as a result of global delays in elective surgeries.

Liquidity

Although there is uncertainty related to the anticipated impact of the recent COVID-19 outbreak on our future results, we believe our business model, our current cash reserves and the recent steps we have taken to strengthen our balance sheet, including our June 2020 and December 2019 equity offerings, leave us well-positioned to manage our business through this crisis as it continues to unfold. We believe our existing balances of cash, including our short-term investments, and our currently anticipated operating cash flows will be sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months.

31

We continue to monitor the rapidly evolving situation and guidance from international and domestic authorities, including federal, state and local public health authorities and may take additional actions based on their recommendations. In these circumstances, there may be developments outside our control requiring us to adjust our operating plan. As such, given the dynamic nature of this situation, we cannot reasonably estimate the impacts of COVID-19 on our financial condition, results of operations or cash flows in the future.

Other Trends and Uncertainties

From time to time we acquire, make investments in or license other technologies, products and business that may enhance our capabilities, complement our current products or expand the breadth of our markets or customer base. As a result of these transactions, we may record certain intangible assets, including goodwill and trademarks, which are subject to annual impairment testing. Impairment is based on our current assessment of the expected future cash flows based on recent results and other specific market factors. Although we have not recorded any impairment charges to date, the most recently prepared assessment indicates our passing rate has narrowed for certain intangible assets. We believe that the expected future cash flows represent management’s best estimate; however, if actual results differ materially from these estimates, we could record an impairment charge which could be material to our consolidated financial statements and have an adverse impact on our results of operations.

Emerging Growth Company and Smaller Reporting Company Status

We will qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”) until December 31, 2022. For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company. The JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Summary of Statements of Operations for the Three Months Ended March 31, 2022 and 2021

The following table sets forth our results of operations for the three months ended March 31, 2022 and 2021:
Three Months Ended March 31,
20222021Increase
(Decrease)		%
Net revenue$23,417 $21,462 $1,955 9 %
Cost of revenue4,851 5,137 (286)(6)%
Sales and marketing expenses9,758 8,949 809 9 %
General and administrative expenses13,167 12,041 1,126 9 %
Research and development expenses2,027 1,308 719 55 %
Other (income) expenses3,031 4,718 (1,687)(36)%
Provision for income taxes (benefit)(317)(312)(5)(2)%
Net loss$(9,100)$(10,379)$(1,279)(12)%
32


Net Revenue

The following tables set forth our net revenue by geography and product category for the three months ended March 31, 2022 and 2021:
Three Months Ended March 31,
Product sales by geographic location:20222021
U.S.$18,188 $16,839 
International5,229 4,623 
Total$23,417 $21,462 
Three Months Ended March 31,
Product sales by category:20222021
Trauma and deformity$16,516 $14,552 
Scoliosis5,983 5,951 
Sports medicine/other918 959 
Total$23,417 $21,462 

Net revenue increased $2.0 million, or 9%, from $21.5 million for the three months ended March 31, 2021 to $23.4 million for the three months ended March 31, 2022. The increase during the three months ended March 31, 2022 was driven primarily by non-elective trauma sales. Additionally, we continue to see the benefit of converting Germany, Austria, and Switzerland to a direct agency sales model.

Trauma and deformity sales increased $2.0 million, or 13%, during the three months ended March 31, 2022, primarily driven by strong trauma and deformity growth across numerous product lines, specifically our PNP Femur, Cannulated Screws and Orthex systems. Scoliosis sales increased $32 thousand, or 1%, during the three months ended March 31, 2022, primarily driven by increased sales of our RESPONSE 4.5/5.0 and sales of the FireFly surgical guides. Sports medicine / other decreased $41 thousand, or 4%, during the three months ended March 31, 2022, primarily driven by a decline in sales from our Telos operations. Nearly all the change in each category was due to an increase or decrease in the unit volume sold and not a result of price changes.

Cost of Revenue and Gross Margin

Cost of revenue decreased $0.3 million, or 6%, from $5.1 million for the three months ended March 31, 2021 to $4.9 million for the three months ended March 31, 2022. The decrease is due primarily to an increased gross margin rate, offset by an increase in volumes sold. Gross margin was 76% for the three months ended March 31, 2021 and 79% for the three months ended March 31, 2022. The change in gross margin is primarily driven by sales through the converted international agencies, favorable purchase price variances, and fewer scoliosis set sales to our international stocking distributors.

Sales and Marketing Expenses

Sales and marketing expenses increased $0.8 million, or 9%, to $9.8 million for the three months ended March 31, 2022 from $8.9 million for the three months ended March 31, 2021. The change in the three month period ended March 31, 2022 was due primarily to increased sales commission expenses, driven by increased unit volumes sold.




33

General and Administrative Expenses

General and administrative expenses increased $1.1 million, or 9%, from $12.0 million for the three months ended March 31, 2021 to $13.2 million for the three months ended March 31, 2022. The increase for the three month period ended March 31, 2022 was due primarily to the addition of personnel and resources to support the continued expansion of our business and an increase in legal and other professional service expense.

Depreciation and amortization expenses increased $0.4 million, or 17%, from $2.5 million for the three months ended March 31, 2021 to $3.0 million for the three months ended March 31, 2022. The increase for the three month period ended March 31, 2022 was primarily due to an increase in depreciation from higher set deployments and the amortization of intangible assets, including licenses which had not yet been put into the market in the first quarter 2021.

Research and Development Expenses

Research and development expenses increased $0.7 million, or 55%, from $1.3 million for the three months ended March 31, 2021 to $2.0 million for the three months ended March 31, 2022. The increase for the three month period ended March 31, 2022 was primarily due to incremental product development and the addition of personnel to support the future growth of the business.

Total Other Expenses

Other expenses were $3.0 million and $4.7 million for the three months ended March 31, 2022 and 2021, respectively, a decrease of $1.7 million or 36%. The decrease in other expense for the three months ended March 31, 2022 was primarily due to the fair value adjustment of contingent consideration, which was driven by the valuation inputs that were lower in comparison to the same period last year. The aggregate of accreted interest expense and fair value adjustments for the three months ended March 31, 2022 and 2021 were $3.0 million and $4.8 million, respectively.

Liquidity and Capital Resources

We have incurred operating losses since inception which resulted in negative cash flows for continuing operations from operating activities of $4.2 million and $1.9 million for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, we had an accumulated deficit of $187.1 million. We anticipate that our losses will continue in the near term as we continue to expand our product portfolio and invest in additional consigned implant and instrument sets to support our expansion into existing and new markets. Since inception, we have funded our operations primarily with proceeds from the sales of our common and preferred stock, convertible securities and debt, as well as through sales of our products. At March 31, 2022, we had cash and cash equivalents, restricted cash and short term investments of $46.4 million.













34



Cash Flows

The following table sets forth our cash flows from operating, investing and financing activities for the periods indicated:
Three Months Ended March 31,
20222021
Net cash used in operating activities$(4,197)$(1,915)
Net cash provided by (used in) investing activities14,303 (5,607)
Net cash provided by (used in) financing activities(33)30 
Effect of exchange rate changes on cash241 155 
Net increase (decrease) in cash$10,314 $(7,337)

Cash Used in Operating Activities

Net cash used in operating activities from continuing operations was $4.2 million and $1.9 million for the three months ended March 31, 2022 and 2021, respectively. The primary use of this cash was to fund our operations related to the development and commercialization of our products in each of these periods. Net cash used for working capital was $2.3 million for the three months ended March 31, 2022 compared to a source of $0.1 million for the three months ended March 31, 2021. During the three months ended March 31, 2022, the primary driver of working capital cash usage was the increase in inventory of $6.8 million and the offset related to trade payables of $5.3 million to support future sales growth. We also saw an increase in the use of cash from the accrued expenses of $0.7 million which was offset by a decrease in prepaid expenses.

Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities for the three months ended March 31, 2022 was $14.3 million compared to a use of cash of $5.6 million for the three months ended March 31, 2021. Net cash provided by investing activities for the three months ended March 31, 2022 consisted primarily of the sale of short-term marketable securities offset by purchases of instrument sets of $4.2 million.

Cash Provided By (Used in) Financing Activities

Net cash used in and provided by financing activities for the three months ended March 31, 2022 and 2021, respectively, was not material to the results of our operations.

Indebtedness

Loan Agreement

Effective December 31, 2021, the Company entered into a Third Amendment (the "Third Amendment") to its Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC, or Squadron (as so amended, the “Loan Agreement”). The Loan Agreement provides a $25.0 million revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears. Prior to the Third Amendment, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61%, and (b) 10.0%. While the Loan Agreement previously provided for certain term loans, there are no longer any outstanding term loan obligations.
35


Borrowings under the revolving credit facility are made under a First Amended and Restated Revolving Note, dated August 4, 2020 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions as further detailed in the Loan Agreement.

The Loan Agreement includes events of default, the occurrence and continuation of any of which provides Squadron with the right to exercise remedies against us and the collateral securing the loans, including cash. These events of default include, among other things, the failure to pay amounts due under the credit facilities, insolvency, the occurrence of a material adverse event, which includes a material adverse change in our business, operations or properties (financial or otherwise) or a material impairment of the prospect of repayment of any portion of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against us in an amount greater than $250 thousand. The occurrence of a material adverse change could result in the acceleration of payment of the debt.

Mortgage Note

In August 2013, pursuant to the purchase of our office and warehouse space, we entered into a mortgage note payable to Tawani Enterprises Inc., the owner of which is a member of Squadron’s management committee. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $15,543, with interest compounded at 5% until maturity in August 2028, at which time a final payment of remaining principal and interest will become due. The mortgage is secured by the related real estate and building. The mortgage balance was $1.0 million and $1.0 million at March 31, 2022 and December 31, 2021, respectively.

Pediatric Orthopedic Business Seasonality

Our revenue is typically higher in the summer months and holiday periods, driven by higher sales of our trauma and deformity and scoliosis products, which is influenced by the higher incidence of pediatric surgeries during these periods due to recovery time provided by breaks in the school year. Additionally, our scoliosis patients tend to have additional health challenges that make scheduling their procedures variable in nature.

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue and expenses during the reporting periods. We monitor and analyze these items for changes in facts and circumstances, and material changes in
36

these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.

ITEM 3.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a "smaller reporting company," we are not required to provide the information required by this item.



ITEM 4.        CONTROLS AND PROCEDURES

a.Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) at the end of the period covered by this quarterly report.

Based on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives, and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

b. Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the period covered by this quarterly report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).
37

PART II. OTHER INFORMATION

ITEM 1.        LEGAL PROCEEDINGS

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.

A discussion of certain of those legal proceedings is contained in Note 12 – Commitments and Contingencies (under the heading “Legal Proceedings”) of the notes to the condensed consolidated financial statements included in Item 1. Financial Statements of Part I of this quarterly report on Form 10-Q, which discussion is incorporated herein by reference.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position, results of operations or cash flows.

ITEM 1A.        RISK FACTORS

In addition to the other information set forth in this quarterly report, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 3, 2022. There have been no material changes to these Risk Factors since the filing of our Annual Report on Form 10-K.

ITEM 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

a. Sale of Unregistered Securities.

None.

b. Use of Proceeds.

None.

c. Issuer Purchases of Equity Securities.

None.

ITEM 3.        DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.        MINE SAFETY DISCLOSURES

None.

ITEM 5.        OTHER INFORMATION

a. Failure to file under Form 8-K.

None.

38

b. Modifications to nomination process.

None.

ITEM 6.        EXHIBITS

The following exhibits are included within this Report or incorporated herein by reference.




39

Exhibit
Number
Description
+
+
+
++
++
101.INS+Inline XBRL Instance Document (The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.)
101.SCH+Inline XBRL Taxonomy Extension Schema Document
101.CAL+Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE+Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)
40


w The schedules to the applicable agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish a copy of any schedule omitted from such agreement to the SEC upon request.

*    Exhibits that describe or evidence management contracts or compensatory plans or arrangements required to be filed as Exhibits to this Report.

+ Filed herewith.

++ Furnished herewith.

41

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 5, 2022By:/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer


May 5, 2022
By:
/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer

42
 EX-10.5 2 hauserjoe2022employmentagr.htm EX-10.5 Document

Employment Agreement

This Employment Agreement (“Agreement”) is made and entered into this 1st day of March, 2022, by and between Joe Hauser (“Employee”) and OrthoPediatrics Corp. (“Employer”).

1.Employment.

Employer hereby employs Employee and Employee hereby accepts employment upon the terms and conditions set forth in this Agreement effective March 1, 2022.

2.Term of Agreement.

Subject to the provisions for termination hereinafter provided, the Term of this Agreement shall commence on March 1, 2022, and continue for a Term of two (2) years. Thereafter, this Agreement shall automatically renew for successive one (1) year Terms, unless notification of intent not to renew is provided in writing by either party to the other party thirty (30) days prior to the end of the Term then in effect.

3.Duties and Responsibilities.

As of March 1, 2022, and for the Term of this Agreement, Employee shall perform the duties of Senior Vice President & General Manager, Trauma & Deformity Correction. Employee shall execute and perform all duties related and necessary to his position(s) as determined by Employer. Employee agrees to abide by all by-laws, policies, practices, procedures, and rules of Employer.

Employee shall devote all of his professional time, efforts, skill and ability to the business of Employer, and shall not, during the Term of this Agreement, be engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage, unless Employee has obtained the prior written approval of Employer. Further, this Paragraph 3 shall not prevent Employee from participating in charitable or other not-for-profit activities as long as such activities do not materially interfere with Employee’s work for Employer.

4.Business Opportunities.

Employee will take no action that deprives Employer of any business opportunities within the scope of Employee’s existing duties and, should Employee be offered or become aware of any such opportunities, Employee shall advise Employer in writing, and Employer shall have the right of first refusal before Employee pursues such opportunity.


[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]



5.Compensation.

Employer shall compensate Employee for services performed during the Term of this Agreement as follows:

A.Annual Salary. Employer shall pay Employee a total Annual Salary at the rate of Three Hundred, Thirty Thousand Dollars ($330,000.00) (minus all applicable deductions and withholdings, including federal, state, and local taxes, and FICA) per year, payable in accordance with Employer’s normal payroll policies. Subsequent to the end of the first calendar year of this Agreement, i.e. 2022, Employer shall review the Annual Salary at a minimum of once per Term for increase consideration.

B.Bonus Eligibility. Employee shall be eligible to earn bonus compensation as determined by the Employer’s Compensation Committee (the “Bonus”). Unless expressly provided otherwise in the Bonus program document, and except as otherwise provided in Section 10.B below, Employee must remain employed by Employer on the date of payment to earn and become entitled to receive payment of any such Bonus.

C.Benefits. Employee shall be entitled to all benefits provided to similarly situated full-time employees of Employer, in accordance with the terms and conditions of the benefit programs and Employer’s policies, excluding any severance pay program or similar termination benefits. This currently includes, but is not limited to, paid holidays, paid vacation and health and welfare benefits. Employee understands and agrees that all benefits are subject to change from time to time at the sole discretion of Employer.

6.Expense Reimbursement.

Employer shall reimburse Employee for all reasonable out-of-pocket expenses that are incurred by Employee in providing services to Employer hereunder; provided, however, that Employee provides Employer with reasonable documentation necessary to support such expenses. All expense reimbursement shall be paid to Employee consistent with Employer’s expense reimbursement policy, in effect from time to time.

7.Confidential Information and Return of Property.

Employee acknowledges that in the course of his employment with Employer, he will occupy a position of trust and confidence and will have access to and may develop Confidential Information of actual or potential value to, or otherwise useful to, Employer. “Confidential Information” means information that the Employer owns or possesses, that it uses or is potentially useful in its business, that it treats as proprietary, private or confidential, and that is not generally known to the public, including, but not limited to, trade secrets (as defined by the Indiana Trade Secrets Act, Ind. Code sec. 24-2-3-1, et. seq.), information relating to the
15241890v1
2

Employer’s business plans, financial condition, operating and other costs, sales, pricing, marketing, ideas, research records, plans for service improvements and development, lists of actual or potential customers, actual and potential customer usage and requirements, customer records, lists of referral sources, referral source records, information on product and product development, inventions, trade secrets, and any other information which derives independent economic value, either actual or potential. Information supplied to Employee from outside sources and/or third parties will also be presumed to be Confidential Information unless and until Employer designates it otherwise.

Employee agrees to use Confidential Information solely in the course of his duties as an employee of Employer and in furtherance of Employer’s business. Employee hereby further agrees that the above-referenced information will be kept confidential at all times during the Term of this Agreement and thereafter, that he will not disclose or communicate to any third party any of the Confidential Information and will not make use of the Confidential Information on his own behalf or on the behalf of a third party.

Employee agrees that all Confidential Information is and shall remain the exclusive property of Employer. Employee agrees to return to Employer on or before Employee’s termination of employment with Employer all Employer property, information and documents, including and without limitation, all reports, files, memoranda, records, software, hardware, credit cards, keys, computer access codes or disks, instruction or operational manuals, handbooks or manuals, written financial information, business plans or other physical and personal property which Employee received or prepared or helped prepare in connection with his employment with Employer; and Employee agrees that he will not retain any copies, duplicates, reproductions or excerpts thereof.

8.Restrictive Covenant.

Employee acknowledges and agrees that in consideration of Employee signing this Agreement and agreeing to its provisions, including the provisions set forth in this Section 8, Employer is paying Employee severance benefits upon termination by Employer without Cause pursuant to Section 10B hereof. Employee also acknowledges and agrees that such consideration is (a) adequate consideration to support the restrictive covenant set forth herein, (b) different from and in addition to any payment or benefits that Employee already was receiving or had any preexisting right to receive, and (c) consideration that Employee would not receive or have any right to receive if Employee were to choose not to sign this Agreement. Employee acknowledges that during his employment with Employer, Employee will have extensive access to Employer’s Confidential Information and may develop business relationships with Employer’s customers. As a result of the extensive access to Confidential Information and the development of business relationships, Employee agrees that during the Term of this Agreement, and for a period of one (1) year from the date of Employee’s termination of employment, Employee shall not, without the prior written consent of Employer, directly or indirectly, for himself or on behalf of any other person, entity or vendor:

15241890v1
3


A.Employ, solicit, contact, or communicate with, for the purpose of hiring, employing or engaging, any individual who is an employee, commissioned agent, or independent contractor of Employer, or who has been, within the twelve (12) month period immediately preceding Employee’s termination of employment.

B.Compete with Employer by participating in any manner in the provision of the business Employee conducted on behalf of Employer, including, but not limited to, the design, manufacture or marketing of orthopedic products for children, for any entity or company, or establish a financial interest in (as an owner, stockholder, partner, lender, or other investor, director, officer, employee, independent contractor, consultant, agent or otherwise) any entity or company, which is in direct or indirect competition with the business interests of Employer with respect to the design, manufacture or marketing of orthopedic products for children, to the extent such entity or company operates within the geographical area:
1.Where Employer (a) conducts its business activity on the date of Employee’s termination, or (b) contemplated conducting its business activity at any time during the twelve (12) month period immediately preceding Employee’s termination of employment; and

2.Where Employee (a) did business on behalf of Employer at the time of Employee’s termination of employment, or at any time during the twelve (12) month period immediately preceding Employee’s termination of employment, or (b) which Employee had access to any Confidential Information regarding.

C.Contact, canvas, solicit, or accept business with respect to the sale, design, manufacture or marketing of orthopedic products for children from any Customer or Potential Customer of Employer if such business would be of the type then being carried on by Employer and which was performed by Employee on behalf of Employer.

D.Induce, cause, advise, or otherwise influence any Customer or Potential Customer of Employer to cease doing business with Employer.

The term “Customer” as used herein shall refer to any entity or company: (1) who Employer provides services or products to at the time of Employee’s termination of employment or at any time during the twelve (12) month period immediately preceding Employee’s termination of employment; and (2) which Employee did business with on behalf of Employer at the time of Employee’s termination of employment or at any time during the twelve (12) month period immediately preceding Employee’s termination of employment, or which Employee had access to any Confidential Information regarding.

The term “Potential Customer” as used herein shall refer to any entity or company: (1) who Employer has solicited, approached, or contracted concerning the possibility of doing business at the time of Employee’s termination of employment or at any time during the twelve (12) month period immediately preceding Employee’s termination of employment; and (2) which Employee

15241890v1
4


was involved in any such solicitation, approach or contact, or which Employee had access to any Confidential Information regarding.

Employee acknowledges and agrees that the restricted period of time, the geographical scope, and the definitions of “Customer” and “Potential Customer” as used in this Paragraph 8 are reasonable.

9.Breach of Agreement.

A.Employee acknowledges that any breach of Paragraphs 7 or 8 of this Agreement, including all subparagraphs thereof, by Employee may cause irreparable damage to Employer and that the legal remedies available to Employer will be inadequate. Therefore, in the event of any threatened or actual breach of Paragraphs 7 or 8 of this Agreement by Employee, Employee agrees that Employer shall be entitled to specific enforcement of this Agreement through injunctive or other equitable relief in addition to legal remedies, without the need for posting bond. If Employee is found, by a court of competent jurisdiction, to have breached any of the terms of Paragraphs 7 or 8 of this Agreement, Employee agrees to pay Employer reasonable attorney’s fees and costs incurred in seeking relief from Employee’s breach of Paragraphs 7 or 8 of this Agreement, including all subparagraphs thereof. Further, the restricted periods of time in Paragraph 8 of this Agreement shall be extended by one additional day for each day a court of competent jurisdiction finds Employee to have been in breach of Paragraph 8 of this Agreement.

B.Employee and Employer hereby submit to the jurisdiction and venue of the Marion County, Indiana Courts and the United States District Court for the Southern District of Indiana, as applicable, in any cause of action, claim, controversy, or dispute arising out of or relating to this Agreement or the breach thereof, including those identified in Paragraph 9.A of this Agreement, and hereby waive any right to a jury trial.

10.Termination and Severance Benefits.

A.Termination by Employer for Cause or Resignation by Employee without Good Reason, or due to Employee’s Death or Disability. The Term and Employee’s employment hereunder may be terminated by Employer for Cause and shall terminate automatically upon Employee’s resignation without Good Reason; provided, that Employee will be required to give Employer at least thirty (30) days’ advance written notice of a resignation without Good Reason. In addition, the Term and Employee’s employment hereunder may be terminated by Employer upon the Employee’s Disability, and shall terminate automatically upon Employee’s death (for purposes of clarity, Employee and Employer acknowledge and agree that a termination due to Disability or death shall not constitute a termination without Cause for purposes of Paragraph 10.B below). Upon termination for Cause or resignation without Good Reason, or termination due to Disability or death, Employee shall only receive the portion of his Annual Salary earned through the

15241890v1
5


Termination Date and such employee benefits, if any, as to which Employee may be entitled under the terms of the applicable plans (the amounts of Annual Salary and any such employee benefits being referred to as “Accrued Compensation”). For the purposes of this Agreement, “Termination Date” shall mean the actual date that Employee’s employment with the Employer and its affiliates terminates for any reason.

As used in this Agreement “Cause” exists in the event of:

1.An act or omission by the Employee that constitutes deliberate or willful misconduct, a breach of fiduciary trust for the purpose of gaining a personal profit, or a violation of any law, rule or regulation;

2.An act or omission by the Employee that materially and adversely affects the best interests of the Employer;

3.An act or omission by the Employee that, under the circumstances, would make it unreasonable to expect Employer to continue to employ the Employee, including without limitation, (i) the commission of any crime (other than minor vehicular violations), (ii) the commission or attempted commission of any act of fraud, embezzlement, neglect or negligence in the performance of Employee’s duties or (iii) any act of malfeasance, substance abuse, sexual harassment, discrimination, or moral turpitude that, in Employer’s reasonable judgment, reflects adversely on the reputation of Employer;

4.Material breach of any provision of this Agreement by Employee; or

5.Willful and continued failure to perform substantially Employee’s duties if such failure continues for a period of thirty (30) calendar days after Employer delivers to Employee a written demand for substantial performance, specifically identifying in such written demand the manner in which Employee has not substantially performed his duties.

As used in this Agreement, “Disability” shall mean that Employee, because of accident, disability, or physical or mental illness, is incapable of performing Employee’s duties to Employer or any affiliate, as determined by the Employer. Notwithstanding the foregoing, Employee will be deemed to have become incapable of performing Employee’s duties to Employer or any affiliate if (A) Employee is incapable of so doing for (1) a continuous period of ninety (90) days and remains so incapable at the end of such ninety (90) day period or (2) periods amounting in the aggregate to ninety (90) days within any one period of one hundred twenty (120) days and remains so incapable at the end of such aggregate period of one hundred twenty
(120) days, (B) Employee qualifies to receive long-term disability payments under the long-term disability insurance program, as it may be amended from time to time, covering employees of Employer or an affiliate to which the Employee provides

15241890v1
6


services or (C) Employee is determined to be totally disabled by the Social Security Administration.

B.Termination by Employer without Cause. Employer may immediately terminate Employee’s employment without Cause. If, during the Term of this Agreement, Employee’s employment is terminated by Employer without Cause (other than due to death or Disability), including if Employer declines to renew the Term of the Agreement, then Employee shall be entitled to receive the Accrued Compensation. In addition, subject to Employee’s continuing compliance with the covenants contained in Paragraphs 7 and 8 of this Agreement and any other similar applicable restrictive covenants with Employer or an affiliate, and the execution by Employee of a binding general waiver and release of claims in a form acceptable to Employer (the “Release”) within the time period specified by Employer at the time of the Termination Date (which shall be no longer than 50 days after the Termination Date) and the expiration of any applicable revocation period with respect to the Release, if Employee’s employment terminates pursuant to this Paragraph 10.B, then Employee shall be entitled to receive:

1.Payment of the Bonus, if any, that was earned by Employee in any fiscal year ending prior to the Termination Date but remains unpaid as of the Termination Date, payable in a lump sum within seventy (70) days after the Termination Date.

2.A pro-rated Bonus, if any, upon the satisfaction of any pre-established performance objectives at the end of the applicable bonus performance period; such payable pro-rata portion of the Bonus shall be determined by multiplying the Bonus amount by a fraction equal to the number of days of Employee’s employment during such applicable performance period divided by the total number of days in the applicable performance period. Payment of any pro- rated Bonus under this paragraph shall be made in the calendar year following the year in which the services were performed, when bonuses are generally paid to similarly situated employees.

3.An amount equal to twelve (12) months of the Employee’s then-current Annual Salary, payable in twelve (12) substantially equal monthly installments commencing with the first regular payroll period following the expiration of any applicable revocation period with respect to the Release, and in any event, if at all, within seventy (70) days after the Termination Date.

4.Provided that Employee elects, and to the extent that he is and remains eligible for, continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) and Employer’s group health plan, payment of that part of the COBRA premiums for such continued coverage of Employee (and, if applicable as of the Termination Date, his dependents) that exceeds the amount that Employee would pay for such coverage if he were an active employee of Employer (“COBRA Subsidies”), starting on the first day

15241890v1
7


following the date on which Employee’s coverage under that plan as an active employee of Employer ends, and ending on the earlier of (A) the date that twelve (12) months of such COBRA Subsidies have been paid, or (B) the date on which Employee’s right to continuation coverage under COBRA ends. Employee agrees and acknowledges that for so long as Employee is covered by COBRA and receiving severance payments under Paragraph 10.B.3, the amount that Employee would pay for coverage under Employer’s group health plan if he were an active employee of Employer shall be deducted from such severance payments, and that this coverage under Employer’s group health plan shall run concurrently with such plan’s obligation to provide continuation coverage pursuant to COBRA. Employee further agrees and understands that this paragraph shall not limit such plan’s obligation to provide continuation coverage under COBRA.

C.Resignation for Good Reason. If, during the Term of this Agreement, Employee resigns from his employment with the Employer and its affiliates for Good Reason in accordance with the requirements of this Paragraph 10.C, then he shall become entitled to the Accrued Compensation. In addition, subject to Employee’s continuing compliance with the covenants contained in Paragraphs 7 and 8 of this Agreement and any other similar applicable restrictive covenants with Employer or an affiliate, and the execution by Employee of Release within the time period specified by Employer at the time of the Termination Date (which shall be no longer than 50 days after the Termination Date) and the expiration of any applicable revocation period with respect to the Release, then Employee shall become entitled to receive the same severance benefits set forth in Paragraph 10.B, subject to the same terms and conditions set forth therein. Employee agrees that before Employee resigns for Good Reason, Employee must give Employer 30 days’ advance written notice of the reason(s) therefor. For purposes of this Agreement, “Good Reason” constitutes the happening of any of the following, without the consent of Employee:

1.Material breach of any provision of this Agreement by Employer;

2.The assignment to Employee of duties inconsistent with Employee’s position as Senior Vice President & General Manager, Trauma & Deformity Correction (including his removal from the Executive Management Committee) or any other action by Employer which results in a material diminution in such position, authority, duties, or responsibilities, excluding an isolated, insubstantial action not taken in bad faith;

3.The material reduction of Employee’s Annual Salary or Bonus or any other action by Employer which results in a material reduction of Employee’s annual compensation; or

4.Employer requiring Employee to be based in a city other than where Employee resides.

15241890v1
8


Notwithstanding the foregoing or any provision to the contrary, Good Reason shall not be deemed to exist unless the notice of termination on account thereof is given to Employer no later than thirty (30) days after the time at which the event or condition purportedly giving rise to Good Reason first occurs or arises; and, provided, that if there exists an event or condition that constitutes Good Reason, Employer shall have thirty (30) days from the date notice of such a termination is given to cure such event or condition and, if Employer does so, such event or condition shall not constitute Good Reason for purposes of this Agreement.

D.Stock Incentive Plan Awards. Upon Employee’s termination of employment, the treatment of all Awards (as that term is defined in Employer’s Stock Incentive Plan (the “Plan”)) granted to Employee while employed by Employer will be determined in accordance with the Plan.

11.Employee Work Product.

Employee agrees that any invention, enhancement, process, method, design and any other creation (hereinafter “Product”) that Employee may develop, invent, discover, conceive or originate, alone or in conjunction with any other person during business hours or on behalf of Employer, during Employee’s employment that relates to the business of Employer now or hereafter carried on by it, or to the use of any product involved therein, shall be the exclusive property of Employer. Employee understands and agrees that in partial consideration of Employee’s employment and for the compensation received, and for continued employment per this Agreement, all such Products shall be the exclusive property of Employer and, thus, subject to patent, copyright, registration or other legal protective custody of Employer.

Employer shall have the authority and this instrument shall operate: (1) to give Employer authority to execute, sell and deliver as the act of Employee, any license agreement, contract, assignment or other instrument in writing that may be necessary or proper with respect to the Product; and (2) to convey to Employer the entire right, title and interest to any such Product. Employee further agrees to hold Employer and its assigns harmless by reason of Employer’s acts pursuant to this Paragraph 11. Employee further agrees that, during his/her employment and any time thereafter, Employee shall cooperate with Employer and its counsel in the prosecution and/or defense of any litigation that may arise in connection with any Product referred to in this Paragraph 11.

12.Choice of Law.

This Agreement shall be interpreted, construed, and governed by the laws of the State of Indiana, regardless of the place of execution or performance.

13.Entire Agreement

This Agreement contains the entire agreement of the parties and supersedes any prior agreements between the parties. This Agreement may not be changed orally, but only by an

15241890v1
9


agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.


14.Severability.

If any provision of this Agreement shall be held by a court of competent jurisdiction to be contrary to law or public policy, the remaining provisions shall remain in full force and effect. It is the intention and desire of the parties that the court treat any provisions of this Agreement which are not fully enforceable as having been modified to the minimum extent deemed necessary by the court to render them reasonable and enforceable and that the court enforce them to such extent.

15.Survival.

This Agreement and the covenants and restrictions contained therein shall survive the termination of this Agreement and/or the termination of Employee’s employment with Employer.

16.Notice.

Any notices, requests, demands, or other communications provided for by this Agreement shall be sufficient if in writing and if (i) delivered by hand to the other party; (ii) sent by facsimile communication with appropriate confirmation of delivery; (iii) sent by registered or certified United States Mail, return receipt requested, with all postage prepaid; or (iv) sent by recognized commercial express courier services, with all delivery charged prepaid; and addressed as follows:

If to Employer: OrthoPediatrics Corp. Attn: General Counsel 2850 Frontier Drive
Warsaw, Indiana 46582
If to Employee: Joe Hauser
6428 Ridgeline Dr.
Hudson, Ohio 44236




17.Section 409A.

Notwithstanding any provisions herein to the contrary, to the maximum extent permitted by applicable law, amounts payable to Employee pursuant to Paragraph 10.B and 10.C shall be made in reliance upon Treas. Reg. Section 1.409A-1(b)(9) (Separation Pay Plans) or Treas. Reg. Section 1.409A-1(b)(4) (Short-Term Deferrals), as applicable. For this purpose, each payment shall be considered a separate and distinct payment. However, to the extent any such payments are treated as nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), then (i) if

15241890v1
10


the 70-day payment period set forth under Paragraph 10.B.1 and 3 commences in one taxable year and ends in another, then payments will not commence until the second taxable year, and (ii) if the Employee is deemed at the time of his separation from service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, then to the extent delayed commencement of any portion of the compensation or benefits to which Employee is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Employee’s compensation or benefits shall not be provided to Employee prior to the earlier of (x) the first business day of the seventh month measured from the date of the Employee’s “separation from service” or (y) the date of Employee’s death. Upon the earlier of such dates, all payments deferred pursuant to this Paragraph 17 shall be paid in a lump sum to Employee, and any remaining payments due under the Agreement shall be paid as otherwise provided herein.

In addition, any reimbursements made or in-kind benefits provided under this Agreement shall be made in accordance with then-current Employer policy, but to the extent such reimbursements or in-kind benefits constitute nonqualified deferred compensation subject to Section 409A, then in no event shall any reimbursements be made later than the end of the calendar year following the year in which the expense was incurred, the amounts eligible for reimbursement or in-kind benefits provided in one year shall not affect the amounts eligible for reimbursement or in-kind benefits to be provided in any subsequent year, and the right to reimbursements or in-kind benefits shall not be subject to liquidation or exchange for another benefit.

The parties acknowledge and agree that, to the extent applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code and the regulations and other interpretive guidance issued thereunder. Employee shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on Employee or for his account in connection with this Agreement (including any taxes and penalties under Code Section 409A), and neither Employer nor any of its subsidiaries or affiliates shall have any obligation to indemnify or otherwise hold Employee harmless from any or all of such taxes or penalties. Employer makes no representations concerning the tax consequences of Employee’s participation in this Agreement under any Federal, state or local law.

18.Acknowledgement.

Employee represents and acknowledges that Employee has had adequate time to review this Agreement, Employee has had the opportunity to ask questions and receive answers from Employer regarding this Agreement, and Employee has had the opportunity to consult with legal advisors of his choice concerning the terms and conditions of this Agreement.

This Agreement is intended to supersede and replace all prior agreements, understandings and arrangements between or among Employer, or any agent thereof, and the Employee, or any agent thereof, relating to the employment of Employee.
15241890v1
11


image_0.jpgimage_1.jpgIN WITNESS WHEREOF, the parties hereto have voluntarily executed this Agreement as of the day and year first above written. This Agreement may be executed in multiple counterparts and each of which when taken together shall constitute one and the same instrument. One or more counterparts of this Agreement may be delivered via facsimile transmission or electronic mail with the intention that they shall have the same effect as an original executed Agreement.

“EMPLOYER” ORTHOPEDIATRICS CORP.

By:    
Daniel Gerritzen
image_2.jpg
(Printed)
“EMPLOYEE”
Joe Hauser

     

Joe Hauser 3.10.22
image_2.jpg
(Printed)

15241890v1
12
 EX-31.1 3 exhibit311-ceocertificatio.htm EX-31.1 Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Bailey, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer
(Principal Executive Officer)

Date:     May 5, 2022


 EX-31.2 4 exhibit312-cfocertificatio.htm EX-31.2 Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Fred L. Hite, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer
(Principal Financial Officer)

Date:     May 5, 2022


 EX-32.1 5 exhibit321-ceocertificatio.htm EX-32.1 Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the quarterly period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David R. Bailey, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.
/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer
(Principal Executive Officer)

Date:     May 5, 2022


 EX-32.2 6 exhibit322-cfocertificatio.htm EX-32.2 Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the quarterly period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Fred L. Hite, Chief Financial Officer and Chief Operating Officer of the Company, hereby certifies, pursuant to 18 Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.
/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer
(Principal Financial Officer)

Date:     May 5, 2022


 EX-101.SCH 7 kids-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2411407 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2412408 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2113103 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2314302 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2417411 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2118104 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 2319303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2420412 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2421413 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2422414 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2423415 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2124105 - Disclosure - DEBT AND CREDIT ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 2325304 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2426416 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2427417 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2128106 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2429418 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2130107 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2331305 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2432419 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2433420 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2134108 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2335306 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2436421 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2437422 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2138109 - Disclosure - BUSINESS SEGMENT link:presentationLink link:calculationLink link:definitionLink 2339307 - Disclosure - BUSINESS SEGMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2440423 - Disclosure - BUSINESS SEGMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2441424 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 2442425 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) link:presentationLink link:calculationLink link:definitionLink 2143110 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2444426 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2145111 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2147112 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2448428 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2149113 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2450429 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 kids-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 kids-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 kids-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Asset Acquisition [Axis] Asset Acquisition [Axis] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net Income (Loss) Attributable to Parent Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Accrued compensation and benefits Employee-related Liabilities, Current Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Name of each exchange on which registered Security Exchange Name Divestiture purchase price Disposal Group, Including Discontinued Operation, Consideration Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Second Amended Loan Agreement Second Amended Loan Agreement [Member] Second Amended Loan Agreement Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Retirement Benefits [Abstract] NET (DECREASE) INCREASE IN CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Accrued legal settlements Increase (Decrease) In Settlement Liabilities, Current Increase (Decrease) In Settlement Liabilities, Current Scoliosis Spine [Member] Spine [Member] Change in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Subsequent Event Type [Domain] Subsequent Event Type [Domain] Legal settlement expense Litigation Settlement, Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Liability Class [Axis] Liability Class [Axis] Subsequent Events [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Unused commitment fee percentage (as a percent) Line of Credit Facility, Commitment Fee Percentage Income Tax Examination [Table] Income Tax Examination [Table] Equity Award [Domain] Award Type [Domain] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Related Party Transactions [Abstract] Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Outstanding at period start (in shares) Outstanding at period end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated Deficit Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Advertising Costs Advertising Cost [Policy Text Block] Long-term liabilities: Liabilities, Noncurrent [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Related Party [Axis] Related Party [Axis] Estimated market portion opportunities Estimated Market Portion Opportunities Estimated Market Portion Opportunities Property, Plant and Equipment Property, Plant and Equipment [Line Items] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Number of operating segments Number of Operating Segments Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Outstanding at period start (in shares) Outstanding at period end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Contingent consideration, beginning balance Contingent consideration, ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Litigation and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Restricted Stock Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Schedule of restricted stock activity Nonvested Restricted Stock Shares Activity [Table Text Block] Shares available for award (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Escrow Escrow Deposit Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Schedule of product sales by geographic location Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] ApiFix Ltd ApiFix Ltd. [Member] ApiFix Ltd. Goodwill Goodwill [Roll Forward] Plan Name [Axis] Plan Name [Axis] Total debt Long-term debt Long-term Debt Level 1 Fair Value, Inputs, Level 1 [Member] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders' equity Liabilities and Equity Vesting period one Share-based Payment Arrangement, Tranche One [Member] Additional paid-in capital Additional Paid in Capital SUPPLEMENTAL DISCLOSURES Supplemental Cash Flow Elements [Abstract] Impairment of indefinitely-lived tradename assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Accounts payable - trade Increase (Decrease) in Accounts Payable Contingent consideration, measurement input Contingent Consideration, Measurement Input Contingent Consideration, Measurement Input NET LOSS PER SHARE Earnings Per Share [Text Block] Operating expenses: Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Stock option exercise Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Fair value adjustment of contingent consideration Fair value adjustment of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Affiliated Entity Affiliated Entity [Member] Gross profit Gross Profit Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Other assets: Other Assets, Noncurrent [Abstract] Current liabilities: Liabilities, Current [Abstract] Number of related party suppliers Number Of Related Party Entities Suppliers Number Of Related Party Entities Suppliers General and administrative General and Administrative Expense DEBT AND CREDIT ARRANGEMENTS Debt Disclosure [Text Block] STOCKHOLDERS' EQUITY Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Accounting Policies [Abstract] Contractual terms (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Number of reportable segments Number of Reportable Segments Operating lease liability Operating Lease, Liability Document Transition Report Document Transition Report Common stock, $0.00025 par value; 50,000,000 shares authorized; 19,821,298 shares and 19,677,214 shares issued as of March 31, 2022 (unaudited) and December 31, 2021, respectively Common Stock, Value, Issued Total other expenses Nonoperating Income (Expense) Unrecognized compensation expense, weighted average period of recognition (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements Basis of Accounting, Policy [Policy Text Block] Subsequent Event [Table] Subsequent Event [Table] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Restricted stock Restricted Stock [Member] Estimated annual limitation of losses Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation Annual Limit Disposal Group Classification [Axis] Disposal Group Classification [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cover [Abstract] Revenues from External Customers and Long-Lived Assets Revenues from External Customers and Long-Lived Assets [Line Items] Long-term debt with affiliate, net of current portion Notes and Loans, Noncurrent Cash and Cash Equivalents and Short Term Investments Cash and Cash Equivalents, Policy [Policy Text Block] Interest expense, net Interest Income (Expense), Net Income Tax Authority [Axis] Income Tax Authority [Axis] Instruments Technology Equipment [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Structure Medical, LLC Structure Medical, LLC [Member] Structure Medical, LLC Sales to related party Revenue from Related Parties Financial Instrument [Axis] Financial Instrument [Axis] Consideration for acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Office and other equipment Office Equipment [Member] Stock option Stock options Share-based Payment Arrangement, Option [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Document Quarterly Report Document Quarterly Report Measurement Input Type [Domain] Measurement Input Type [Domain] Note payable to Squadron Notes Payable, Other Payables [Member] Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Other expenses: Other Nonoperating Income (Expense) [Abstract] BUSINESS SEGMENT Segment Reporting Disclosure [Text Block] Operating loss Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Stock-based compensation Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Mitchell Designs, Inc Mitchell Designs, Inc [Member] Mitchell Designs, Inc Third Amended Loan Agreement Third Amended Loan Agreement [Member] Third Amended Loan Agreement Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Deferred income taxes Increase (Decrease) in Deferred Income Taxes Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Other income Other Nonoperating Income (Expense) 2017 Plan New 2017 Equity Incentive Plan [Member] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Vilex and Orthex Vilex and Orthex [Member] Vilex and Orthex Award Type [Axis] Award Type [Axis] FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent Accounts receivable - trade Increase (Decrease) in Accounts and Notes Receivable Loss carryforwards Operating Loss Carryforwards Common stock, shares issued (in shares) Common Stock, Shares, Issued City Area Code City Area Code Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Increase of estimated annual limitation of first five years Operating Loss Carryforwards Limitations On Use Estimated Amount Subject to Limitation Annual Limit Increase Depreciable lives (in years) Property, Plant and Equipment, Useful Life Common stock (in dollars per share) Business Acquisition, Share Price Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Business software Software and Software Development Costs [Member] Expected years Contingent Consideration, Measurement Input, Period Contingent Consideration, Measurement Input, Period Measurement Frequency [Domain] Measurement Frequency [Domain] 2007 Plan 2007 Equity Incentive Plan [Member] License Agreements Licensing Agreements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Income Tax Examination Income Tax Examination [Line Items] Statement of Stockholders' Equity [Abstract] Acquisition installment payable, net of current portion Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent Entity Filer Category Entity Filer Category Business Acquisition Business Acquisition [Line Items] Vesting period two Share-based Payment Arrangement, Tranche Two [Member] Discounted cash flow, Monte Carlo Valuation Technique, Discounted Cash Flow [Member] Treasury Bonds US Treasury Securities [Member] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Royalty agreement percentage (as a percent) Research and Development Arrangement Contract to Perform for Others Royalty Agreement Percent Schedule of fair value, liabilities measured on recurring basis, unobservable input reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Other intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Short term investments Short-term Investments Related Party Transaction [Axis] Related Party Transaction [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Provision for income taxes (benefit) Income tax benefit Income Tax Expense (Benefit) Accounts receivable - trade, less allowance for doubtful accounts of $357 and $347, respectively Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Intellectual Property Intellectual Property [Member] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventories, net Inventory, Net Schedule of product sales by category Schedule of Segment Reporting Information, by Segment [Table Text Block] Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Less: current maturities Current portion of long-term debt with affiliate Long-term Debt, Current Maturities Products and Services [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Equity Component [Domain] Equity Component [Domain] Sales and marketing Selling and Marketing Expense Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Transfer of instruments from property and equipment to inventory Transfer Of Property And Equipment To Inventory Statement [Line Items] Statement [Line Items] Impairment charges, indefinite-lived Impairment of Intangible Assets, Finite-lived Current portion of acquisition installment payable Business Combination, Contingent Consideration, Acquisition Installment Payable, Current Business Combination, Contingent Consideration, Acquisition Installment Payable, Current Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Payments to related party Related Party Transaction, Purchases from Related Party Federal and state Domestic Tax Authority [Member] Restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Counterparty Name [Domain] Counterparty Name [Domain] Debt Disclosure [Abstract] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Segment Reporting [Abstract] Intangible asset, useful life (in years) Finite-Lived Intangible Asset, Useful Life EMPLOYEE BENEFIT PLAN Retirement Benefits [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Schdule of reconciliation of basic and diluted net loss per share attributable to common stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Options granted (in shares) Options, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Other comprehensive loss, net of tax Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Entity Ex Transition Period Entity Ex Transition Period Vesting [Axis] Vesting [Axis] Title of Each Class Title of 12(b) Security Total assets Assets Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Firefly Technology Firefly Technology [Member] Firefly Technology Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Payments on mortgage notes Repayments of Notes Payable Document Type Document Type Products and Services [Domain] Product and Service [Domain] Research and development Research and Development Expense Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Secured Overnight Financing Rate Secured Overnight Financing Rate [Member] Secured Overnight Financing Rate Sports medicine/other Sports Medicine And Other [Member] Sports Medicine And Other [Member] Contingent Consideration Business Combination, Contingent Consideration, Liability Total long-term liabilities Liabilities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Sample inventory Sample Inventory [Member] "Emerging Growth Company" and "Smaller Reporting Company" Reporting Requirements Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy [Policy Text Block] Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Tax credit carryforward Tax Credit Carryforward, Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Impacted children Cumulative Children Impacted, Count Cumulative Children Impacted, Count Geographical [Axis] Geographical [Axis] Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted Weighted average common stock - basic (in shares) Weighted average number of shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic State State and Local Jurisdiction [Member] Acquisition installment payable Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable Vesting [Domain] Vesting [Domain] Amortizable Intangible Assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] International Non-US [Member] SUBSEQUENT EVENTS Subsequent Events [Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Restricted stock exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercisable Number Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Deferred income taxes Deferred Income Tax Liabilities, Net Related Party Transaction Related Party Transaction [Line Items] Weighted-average remaining contractual terms (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Corporate Bonds Corporate Debt Securities [Member] FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] Accounts payable - trade Accounts Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization Schedule of fair value, assets and liabilities measured on recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Acquisition Payable and Contingent Consideration Business Combinations Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Issuance of common stock Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Cost of revenue Cost of Goods and Services Sold Document Period End Date Document Period End Date Restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Number of Reporting Units Number of Reporting Units Purchases of licenses Payments to Acquire Intangible Assets Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Schedule of Property and equipment, depreciable lives Property, Plant and Equipment [Table Text Block] Short term investments Investments, Fair Value Disclosure Long-term Purchase Commitment Long-term Purchase Commitment [Line Items] Finite lived intangible asset useful life extension period (in years) Finite-Lived Intangible Asset, Useful Life Extension Period Finite-Lived Intangible Asset, Useful Life Extension Period Property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Other long-term liabilities Other Liabilities, Noncurrent Schedule of long-term debt Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument Debt Instrument [Line Items] Trading Symbol(s) Trading Symbol Earnings Per Share [Abstract] Payments on note with affiliate Repayments of Related Party Debt Trauma and deformity Trauma and Deformity [Member] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Related Party Transaction [Domain] Related Party Transaction [Domain] Trademarks Trademarks [Member] Sale of short-term marketable securities Proceeds from Sale of Debt Securities, Available-for-sale Team note B Team Note B [Member] Team Note B Outstanding at period start, weighted-average exercise price (in dollars per share) Outstanding at period end, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Long-term debt with affiliate, net of current maturities Long-term Debt, Excluding Current Maturities Patents Patents [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Stock-based compensation expense Share-based Payment Arrangement, Expense Cost of Revenue Cost of Goods and Service [Policy Text Block] Total other assets Assets, Noncurrent, Excluding Property, Plant and Equipment Assets, Noncurrent, Excluding Property, Plant and Equipment Entity Current Reporting Status Entity Current Reporting Status Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Other Other Debt Obligations [Member] Restricted cash Restricted Cash, Current Counterparty Name [Axis] Counterparty Name [Axis] Cash and restricted cash, beginning of year Cash and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents U.S. UNITED STATES Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Present value discount rate Measurement Input, Discount Rate [Member] Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Gross Intangible Assets Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Three month LIBOR London Interbank Offered Rate (LIBOR) [Member] Weighted-Average Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Disposal Group Classification [Domain] Disposal Group Classification [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition - United States and International Revenue from Contract with Customer [Policy Text Block] Stock option exercise (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted average common stock - diluted (in shares) Weighted average number of shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair Value, Recurring Fair Value, Recurring [Member] INCOME TAXES Income Tax Disclosure [Text Block] Related Party [Domain] Related Party [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Schedule of stock option activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Debt instrument, basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Schedule of antidilutive securities excluded from computation of net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive loss: Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Entity Address, Address Line One Entity Address, Address Line One Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Building and building improvements Building and Building Improvements [Member] Changes in certain current assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Unrealized loss on short-term investments Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Entity Shell Company Entity Shell Company Purchase commitment, remaining minimum amount committed Purchase Commitment, Remaining Minimum Amount Committed Total current liabilities Liabilities, Current Cash consideration Payments to Acquire Businesses, Gross Vilex Vilex [Member] Vilex Revolving credit facility Line of Credit Facility, Maximum Borrowing Capacity Foreign currency translation impact Goodwill, Foreign Currency Translation Gain (Loss) Employer contribution as a percentage of employees' salary (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Segment Reporting Information Segment Reporting Information [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement [Table] Statement [Table] Asset Backed Securities Asset-backed Securities [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Squadron Squadron [Member] Squadron Sales and Marketing Expenses Sales And Marketing Expense Policy [Policy Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable [Policy Text Block] Subsequent Event Subsequent Event [Member] Mortgage payable to affiliate Mortgages [Member] Estimated limitation on losses generated prior to ownership change date Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Amortizable intangible assets, net Net Intangible Assets Finite-Lived Intangible Assets, Net Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Volatility factor Measurement Input, Price Volatility [Member] Schedule of fair value measurement inputs and valuation techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Inventories, net Inventory, Policy [Policy Text Block] Schedule of goodwill Schedule of Goodwill [Table Text Block] BUSINESS Nature of Operations [Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Current portion of long-term debt with affiliate Long-term Debt, Current Maturities, Related Party Long-term Debt, Current Maturities, Related Party Computer equipment Computer Equipment [Member] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Monthly interest and principal installments Debt Instrument, Periodic Payment EX-101.PRE 11 kids-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 image_0.jpg begin 644 image_0.jpg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end GRAPHIC 13 image_1.jpg begin 644 image_1.jpg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end GRAPHIC 14 image_2.jpg begin 644 image_2.jpg MB5!.1PT*&@H -24A$4@ !A$ +" ( #^]SL3 <4E$051X7NW8 ML1$ ( P#,?9?&BXEOT*DSA[AS_T= )9)()I&U T # ,@E$TXBZ 0 M %@F@6@:40\ UM., "C-" (#2C HS0@ " THP C*,T( @-*, *@'*(5QA8-0\E\ 245.1*Y"8((! end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
 3 Months Ended
Mar. 31, 2022
May 03, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-38242  
Entity Registrant Name OrthoPediatrics Corp  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-1761833  
Entity Address, Address Line One 2850 Frontier Drive  
Entity Address, City or Town Warsaw  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46582  
City Area Code 574  
Local Phone Number 268-6379  
Title of Each Class Common Stock, $0.00025 par value per share  
Trading Symbol(s) KIDS  
Name of each exchange on which registered NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   20,229,901
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Central Index Key 0001425450  
Current Fiscal Year End Date --12-31  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS
€ in Thousands, $ in Thousands
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Current assets:    
Cash and cash equivalents $ 17,957 $ 7,641
Restricted cash 1,363 1,365
Short term investments 27,068 45,902
Accounts receivable - trade, less allowance for doubtful accounts of $357 and $347, respectively 17,911 17,942
Inventories, net 64,077 57,569
Prepaid expenses and other current assets 3,048 3,229
Total current assets 131,424 133,648
Property and equipment, net 31,068 28,515
Other assets:    
Amortizable intangible assets, net 53,476 55,494
Goodwill 70,987 72,349
Other intangible assets 14,040 14,268
Total other assets 138,503 142,111
Total assets 300,995 304,274
Current liabilities:    
Accounts payable - trade 14,578 9,325
Accrued compensation and benefits 4,433 5,351
Current portion of long-term debt with affiliate 139 137
Current portion of acquisition installment payable 12,934 12,862
Other current liabilities 2,249 2,040
Total current liabilities 34,333 29,715
Long-term liabilities:    
Long-term debt with affiliate, net of current portion 872 907
Acquisition installment payable, net of current portion 14,690 14,309
Contingent consideration 31,480 28,910
Deferred income taxes 4,335 4,771
Other long-term liabilities 241 293
Total long-term liabilities 51,618 49,190
Total liabilities 85,951 78,905
Stockholders' equity:    
Common stock, $0.00025 par value; 50,000,000 shares authorized; 19,821,298 shares and 19,677,214 shares issued as of March 31, 2022 (unaudited) and December 31, 2021, respectively 5 5
Additional paid-in capital 396,425 394,899
Accumulated deficit (187,126) (178,026)
Accumulated other comprehensive income 5,740 8,491
Total stockholders' equity 215,044 225,369
Total liabilities and stockholders' equity $ 300,995 $ 304,274
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 357 $ 347
Common stock, par value (in dollars per share) $ 0.00025 $ 0.00025
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 19,821,298 19,677,214
Common stock, shares outstanding (in shares) 19,821,298 19,677,214
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Net revenue $ 23,417 $ 21,462
Cost of revenue 4,851 5,137
Gross profit 18,566 16,325
Operating expenses:    
Sales and marketing 9,758 8,949
General and administrative 13,167 12,041
Research and development 2,027 1,308
Total operating expenses 24,952 22,298
Operating loss (6,386) (5,973)
Other expenses:    
Interest expense, net 566 728
Fair value adjustment of contingent consideration 2,570 4,150
Other income (105) (160)
Total other expenses 3,031 4,718
Loss before income taxes (9,417) (10,691)
Provision for income taxes (benefit) (317) (312)
Net loss $ (9,100) $ (10,379)
Weighted average common stock - basic (in shares) 19,366,911 19,200,231
Weighted average common stock - diluted (in shares) 19,366,911 19,200,231
Net loss per share - basic (in dollars per share) $ (0.47) $ (0.54)
Net loss per share - diluted (in dollars per share) $ (0.47) $ (0.54)
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net loss $ (9,100) $ (10,379)
Other comprehensive loss:    
Foreign currency translation adjustment (2,198) (3,499)
Unrealized loss on short-term investments (553) (123)
Other comprehensive loss, net of tax (2,751) (3,622)
Comprehensive loss $ (11,851) $ (14,001)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Balance (in shares) at Dec. 31, 2020   19,560,291      
Balance at Dec. 31, 2020 $ 234,768 $ 5 $ 388,622 $ (161,766) $ 7,907
Increase (Decrease) in Stockholders' Equity          
Net loss (10,379)     (10,379)  
Other comprehensive loss (3,622)       (3,622)
Stock option exercise (in shares)   2,010      
Stock option exercise 62   62    
Restricted stock (in shares)   97,111      
Restricted stock 1,316   1,316    
Balance (in shares) at Mar. 31, 2021   19,659,412      
Balance at Mar. 31, 2021 $ 222,145 $ 5 390,000 (172,145) 4,285
Balance (in shares) at Dec. 31, 2021 19,677,214 19,677,214      
Balance at Dec. 31, 2021 $ 225,369 $ 5 394,899 (178,026) 8,491
Increase (Decrease) in Stockholders' Equity          
Net loss (9,100)     (9,100)  
Other comprehensive loss (2,751)       (2,751)
Restricted stock (in shares)   144,084      
Restricted stock $ 1,526   1,526    
Balance (in shares) at Mar. 31, 2022 19,821,298 19,821,298      
Balance at Mar. 31, 2022 $ 215,044 $ 5 $ 396,425 $ (187,126) $ 5,740
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
OPERATING ACTIVITIES    
Net loss $ (9,100) $ (10,379)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,961 2,539
Stock-based compensation 1,526 1,316
Fair value adjustment of contingent consideration 2,570 4,150
Acquisition installment payable 453 644
Deferred income taxes (317) (312)
Changes in certain current assets and liabilities:    
Accounts receivable - trade 2 653
Inventories (6,750) (2,508)
Prepaid expenses and other current assets 112 708
Accounts payable - trade 5,258 2,058
Accrued legal settlements 0 (1,092)
Accrued expenses and other liabilities (690) 446
Other (222) (138)
Net cash used in operating activities (4,197) (1,915)
INVESTING ACTIVITIES    
Sale of short-term marketable securities 18,500 0
Purchases of licenses 0 (2,858)
Purchases of property and equipment (4,197) (2,749)
Net cash provided by (used in) investing activities 14,303 (5,607)
FINANCING ACTIVITIES    
Proceeds from exercise of stock options 0 62
Payments on mortgage notes (33) (32)
Net cash (used in) provided by financing activities (33) 30
Effect of exchange rate changes on cash 241 155
NET (DECREASE) INCREASE IN CASH 10,314 (7,337)
Cash and restricted cash, beginning of year 9,006 30,132
Cash and restricted cash, end of period 19,320 22,795
SUPPLEMENTAL DISCLOSURES    
Cash paid for interest 13 15
Transfer of instruments from property and equipment to inventory $ (54) $ 57
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESS
OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSETM Spine, BandLocTM, Pediatric Nailing Platform | Femur, Orthex, QuickPackTM and ApiFix® Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation.

We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 243,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300 opportunity globally, including over $1,500 in the United States.

Our largest investor is Squadron, a private investment firm based in Granby, Connecticut.
A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. As a result of the pandemic, we have experienced significant business disruption. For example, in preparation for COVID-19-related hospitalizations, various governments, governmental agencies and hospital administrators required certain hospitals to postpone some elective procedures. As a majority of our products are utilized in elective surgeries or procedures, the deferrals of such surgeries and procedures have had, and may continue to have, a significant negative impact on our business and results of operations. Despite the impact COVID-19 has had on our business, we continued to invest in research and development, invest in our people, and take steps to position ourselves for long-term success. We continue to train and educate our sales team and our surgeons on our products. We have continued to focus on developing innovative solutions, acquired multiple enabling technologies, invested in both new and existing partnerships and continued to deploy additional consigned instrument and implant sets in furtherance of our strategy. The extent to which COVID-19 may continue to negatively impact the Company's consolidated financial position, results of operations or cash flows is uncertain and will be closely monitored.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V.,
Orthex, LLC, Telos Partners, LLC and ApiFix, Ltd. (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2022 and 2021 and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $187,126 and $178,026 as of March 31, 2022 and December 31, 2021, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short term investments, at March 31, 2022 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months.

Use of Estimates

Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.

Foreign Currency Transactions

We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense.

Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland,
Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss.

Revenue from Contracts with Customers

In accordance with ASC 606, "Revenue from Contracts with Customers," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement.
Revenue Recognition – International

Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns.
Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when title passes upon shipment. Pricing for each customer is dictated by a unique pricing agreement.

Cash, Cash Equivalents and Short Term Investments

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value.

The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the
next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations.

Restricted Cash

In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the March 31, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 12 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 100 Euro at its Netherlands entity for potential Italian tenders.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.

The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.

Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.   

The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment
payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 4 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis.

Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.

In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.

Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.
Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years

Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses, including Band-Lok, the value of internally developed software, customer relationships, and non-competition agreements related to the acquisition of Orthex, and customer relationships and non-competition agreements related to the acquisitions of Telos and ApiFix. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period.

Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges were recorded in any of the periods presented.

Goodwill and Other Intangible Assets

Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No impairment charges were recorded in any of the periods presented.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof.

We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented.
Acquisition Payable and Contingent Consideration

Upon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. The amount of expense related to acquisition installment payables recorded in interest expense, net for the three months ended March 31, 2022 and March 31, 2021 were $453 and $644, respectively. The fair value adjustments of contingent consideration for the three months ended March 31, 2022 and March 31, 2021 were expense adjustments of $2,570 and $4,150, respectively.

Cost of Revenue

Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.

Advertising Costs

Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.

Research and Development Costs

Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.

Stock-Based Compensation

Prior to our Initial Public Offering ("IPO") in October 2017, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award.
Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.

Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.

Litigation and Contingencies

Accruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period.

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance.
We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease.

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.

“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company.

Recent Accounting Pronouncements

In October 2021, the FASB issued ASU No. 2021-08 "Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.

In May 2021, the FASB issued ASU No. 2021-04 "Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments". The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill

Changes in the carrying amount of goodwill for the three months ended March 31, 2022 were as follows:
Total
Goodwill at January 1, 2022$72,349 
Foreign currency translation impact(1,362)
Goodwill at March 31, 2022
$70,987 
Intangible Assets

As of March 31, 2022, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.5 years$43,656 $(6,287)$37,369 
Intellectual Property9.8 years9,834 (1,584)8,250 
License Agreements5.2 years10,674 (2,817)7,857 
Total amortizable assets$64,164 $(10,688)$53,476 

As of December 31, 2021, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.7 years$44,493 $(5,664)$38,829 
Intellectual Property10.1 years9,847 (1408)8,439 
License Agreements5.5 years10,674 (2,448)8,226 
Total amortizable assets$65,014 $(9,520)$55,494 

Licenses are tied to product launches and do not begin amortizing until the product is launched to the market.
Trademarks are non-amortizing intangible assets which were $14,040 and $14,268 as of March 31, 2022 and December 31, 2021, respectively. Trademarks are recorded in Other Intangible assets on the condensed consolidated balance sheets. The change in balance during the three months ended March 31, 2022 was the result of foreign currency translation of the ApiFix trademark.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE OF FINANCIAL INSTRUMENTS
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.

The following table summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021.
March 31, 2022
Level 1Level 2Level 3Total
Financial Assets
Short term investments
Corporate Bonds$13,776 $— $— $13,776 
Treasury Bonds$7,445 $— $— $7,445 
Asset Backed Securities$— $5,261 $— $5,261 
Other$586 $— $— $586 
Financial Liabilities
Contingent Consideration$— $— $31,480 $31,480 
December 31, 2021
Level 1Level 2Level 3Total
Financial Assets
Short term investments
Corporate Bonds$22,476 $— $— $22,476 
Treasury Bonds$14,317 $— $— $14,317 
Asset Backed Securities$— $8,272 $— $8,272 
Other$837 $— $— $837 
Financial Liabilities
Contingent Consideration$— $— $28,910 $28,910 

The Company's level 1 assets consist of cash equivalents which are generally comprised of short-term, liquid investments with original maturity of three months or less at inception and other short term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months.

The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date using an option pricing model and a Monte Carlo simulation based on forecasted annual revenue, expected volatility and discount rates. The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement. The adjustments in the fair value of the contingent consideration payments included expense adjustment of $2,570 and $4,150 for the three month periods ended March 31, 2022 and March 31, 2021, respectively, in other expenses on the condensed consolidated statements of operations.

The following table summarizes the change in fair value of Level 3 instruments in 2022:
Total
Balance at January 1, 2022
$28,910 
Change in fair value of contingent consideration2,570 
Balance at March 31, 2022
$31,480 
The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of March 31, 2022 and December 31, 2021:
March 31, 2022December 31, 2021
Valuation techniquesDiscounted cash flow, Monte Carlo
Present value discount rate(1)
19.3 %18.4 %
Volatility factor46.5 %50.3 %
Expected years2.1 years2.4 years

(1) The present value discount rate includes estimated risk premium.
The estimated fair value reflects assumptions made by management as of March 31, 2022; however, the actual amount ultimately paid could be higher or lower than the fair value of the remaining contingent consideration.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.1
DEBT AND CREDIT ARRANGEMENTS
 3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
DEBT AND CREDIT ARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS
Long-term debt consisted of the following:
March 31, 2022December 31, 2021
Mortgage payable to affiliate$1,011 $1,044 
Less: current maturities139 137 
Long-term debt with affiliate, net of current maturities$872 $907 

Effective December 31, 2021, the Company entered into a Third Amendment (the "Third Amendment") to its Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC, or Squadron (as so amended, the “Loan Agreement”). The Loan Agreement provides a $25,000 revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears. Prior to the Third Amendment, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. While the Loan Agreement previously provided for certain term loans, there are no longer any outstanding term loan obligations.

Borrowings under the revolving credit facility are made under a First Amended and Restated Revolving Note, dated August 4, 2020 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions.
In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At March 31, 2022 the mortgage balance was $1,011 of which current principal of $139 was included in the current portion of long-term debt. As of December 31, 2021, the mortgage balance was $1,044 of which current principal due of $137 was included in the current portion of long-term debt. The aggregate interest expense relating to the notes payable to Squadron and the mortgage note payable to Tawani was $13 and $15 for the three months ended March 31, 2022 and 2021, respectively.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss).

For the three months ended March 31, 2022, the income tax benefit was $317 compared to $312 for the three months ended March 31, 2021. Our effective income tax rate was 3.4% and 2.9% for the three months ended March 31, 2022 and 2021, respectively.

The deferred tax assets were fully offset by a valuation allowance at March 31, 2022 and December 31, 2021, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix. The company has recorded a tax benefit during the period ended March 31, 2022 for losses generated in the foreign jurisdiction. As of December 31, 2021, we had available federal, state and foreign tax loss carryforwards of $114,008, $73,997 and $22,671, respectively. We had available federal tax credits of $176. Net operating losses generated prior to December 31, 2017 will begin to expire in 2028. Federal net operating losses generated after January 1, 2018 will have an indefinite carryforward period. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $23,920 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062. A second ownership change under Section 382 was deemed to occur on December 11, 2018. The estimated annual limitation is $9,736, which is increased by $22,430 annually over the first five years as a result of an unrealized built in gain. NOLs sustained prior to May 30, 2014 will still be constrained by the lower limitation.
Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended March 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Stock Options

The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.
Our stock option activity and related information are summarized as follows:
Weighted-AverageContractual Terms
OptionsExercise Price(in Years)
Outstanding at January 1, 20226,638 $30.97 1.3
Outstanding at March 31, 2022
6,638 $30.97 1.1

Options generally include a time-based vesting schedule permitting the options to vest ratably over three years. At March 31, 2022 and December 31, 2021, all options were fully vested.

There was no stock-based compensation expense on stock options for the three months ended March 31, 2022 and 2021, respectively.


Restricted Stock

Our restricted stock activity and related information are summarized as follows:
Weighted-Average
Remaining
RestrictedContractual Terms
Stock(in Years)
Outstanding at January 1, 2022368,446 1.1
Granted146,425 
Forfeited(2,341)
Vested(120,656)
Outstanding at March 31, 2022
391,874 1.9
Restricted stock exercisable at March 31, 2022
— 

At March 31, 2022, there was $12,443 of unrecognized compensation expense remaining related to our service-based restricted stock awards. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 1.9 years or earlier upon an elimination of the restriction period as a result of a change in control event.
Stock-based compensation expense on restricted stock amounted to $1,526 and $1,440 for the three months ended March 31, 2022 and 2021, respectively. The increase in the stock compensation for the three months ended March 31, 2022 is primarily due to increase in plan participants as we continue to hire employees to support the continued expansion of our business.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.1
NET LOSS PER SHARE
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
The following is a reconciliation of basic and diluted net loss per share:
Three Months Ended
March 31,
20222021
Net loss$(9,100)$(10,379)
Weighted average number of shares - basic and diluted19,366,911 19,200,231 
Net loss per share - basic and diluted$(0.47)$(0.54)

Our basic and diluted net loss per share is computed using the two-class method.  The two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or
losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. 

Because we have incurred a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share. The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented:
Three Months Ended March 31,
20222021
Restricted stock391,874 389,098 
Stock options6,638 10,792 
Total shares398,512 399,890 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS SEGMENT
 3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
BUSINESS SEGMENT BUSINESS SEGMENT
Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No customers accounted for more than 10% of total product sales for the three months ended March 31, 2022 or 2021. No customer accounted for more than 10% of consolidated accounts receivable as of March 31, 2022 and December 31, 2021.

Product sales by source were as follows:
Three Months Ended March 31,
Product sales by geographic location:20222021
U.S.$18,188 $16,839 
International5,229 4,623 
Total$23,417 $21,462 
Three Months Ended March 31,
Product sales by category:20222021
Trauma and deformity$16,516 $14,552 
Scoliosis5,983 5,951 
Sports medicine/other918 959 
Total$23,417 $21,462 
No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three months ended March 31, 2022 and 2021.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS
 3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONSIn addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $316 and $72 for the three months ended March 31, 2022 and 2021, respectively.On December 31, 2019, the Company divested Vilex for $25,000 to an affiliate of Squadron. In conjunction with the divestiture, the Company also entered into an exclusive perpetual license agreement to permit the purchasers of Vilex the ability to access intellectual property and sell products using the external fixation technology of Orthex, LLC to non-pediatric accounts. We had sales and payments related to inventory purchases to Squadron's affiliate, now known as Vilex, LLC, of $8 and $25, respectively, for the three months ended March 31, 2022. We had sales and payments related to inventory purchases to Vilex, LLC of $87 and $189, respectively, for the three months ended March 31, 2021
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.1
EMPLOYEE BENEFIT PLAN
 3 Months Ended
Mar. 31, 2022
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Leases

As of March 31, 2022, the Company has recorded a lease liability of $241 and corresponding right-of-use-asset of $243 on its condensed consolidated balance sheet.

Legal Proceedings

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.

IMED Surgical - Software Ownership Dispute

On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron Capital, LLC (“Squadron”), and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company (the “Plaintiff”), in Broward County, Florida Circuit Court. In the lawsuit, the Plaintiff claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).
In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point & Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent. According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with the Plaintiff.

The Plaintiff, among other things, requests that the defendants be ordered to convey and assign to Plaintiff all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants.

On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent the Plaintiff desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, the Plaintiff initiated an arbitration proceeding. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to the Plaintiff before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order.

Although we believe the IMED lawsuit is without merit and will vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.


Wishbone Medical, Inc. – Patent Infringement Litigation

On October 30, 2020, OrthoPediatrics, along with its wholly-owned subsidiary, Orthex, LLC, filed a lawsuit in federal district court (N.D. Indiana, South Bend Division, Case No. 3:20-cv-00929) against Wishbone Medical, Inc. and Nick A. Deeter (collectively “Wishbone”), claiming infringement of ’377 Patent, unfair competition, false advertising, breach of contract, defamation per se, tortious interference with contractual relationships, and tortious interference with prospective contractual relationships. In early January 2021, OrthoPediatrics amended its lawsuit by adding a declaratory judgment claim of infringement of the ‘377 Patent against Wishbone.

Thereafter, in January 2021, Wishbone filed a motion to dismiss all OrthoPediatrics’ causes of action. In late August 2021, the Court denied Wishbone's motion to dismiss with respect to OrthoPediatrics’ infringement and breach of contract claims and dismissed OrthoPediatrics' remaining causes of action. In late September 2021, Wishbone filed its answer and counterclaims, in part, seeking declaratory judgment of non-infringement and invalidity of the ‘377 Patent, and alleging OrthoPediatrics patent infringement claim(s) against Wishbone was made in bad faith. In mid-October 2021, OrthoPediatrics filed its answer to Wishbone’s counterclaims, denying all of them. Although we believe Wishbone’s counterclaims are without merit and will vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have an adverse effect on our business, operating results and financial condition.
We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

Purchase Obligations and Performance Requirements

As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASHTM Navigation platform, the Company has agreed to a minimum purchase commitment for the first twelve months of that agreement. As of March 31, 2022, the remaining purchase commitment under the agreement was $1,900.

On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three months ended March 31, 2022, the Company recorded an expense of $101 based on current estimates. No expense was recorded for the three months ended March 31, 2021.

Royalties

As of March 31, 2022, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales.
We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of March 31, 2022, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
MD Orthopaedics Acquisition

On April 1, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with OrthoPediatrics Iowa Holdco, Inc., a Delaware corporation and newly-formed wholly-owned subsidiary of the Company (“Merger Sub”), Mitchell Designs, Inc. (“Designs”), an Iowa corporation and the sole shareholder of MD Orthopaedics, Inc., also an Iowa corporation (“MD Ortho”) and John Mitchell, the sole shareholder of Designs (“Mitchell”). MD Ortho has developed and manufactures a portfolio of orthopedic clubfoot products.

Pursuant to the Merger Agreement, Designs merged with and into Merger Sub effective April 1, 2022. Under the terms of the Merger Agreement, the Company paid to Mitchell consideration of (a) $8,200 in cash, and (b) 173,241 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $9,707 (based on the April 1, 2022 closing share price of $56.03).

ApiFix Acquisition Installment Payment

On April 1, 2022, the second-year anniversary of the acquisition of ApiFix, the Company paid $3,233 in cash and issued 185,811 shares of the Company's common stock, representing $10,411 of fair value (based on the April 1, 2022 closing share price of $56.03), to fulfill its installment obligation to ApiFix. This was the first installment payment paid since the acquisition.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V.,
Orthex, LLC, Telos Partners, LLC and ApiFix, Ltd. (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2022 and 2021 and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.
The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern.
Use of Estimates Use of EstimatesPreparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.
Foreign Currency Transactions
Foreign Currency Transactions

We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense.

Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland,
Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss.
Revenue Recognition - United States and International
Revenue from Contracts with Customers

In accordance with ASC 606, "Revenue from Contracts with Customers," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement.
Revenue Recognition – International

Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns.
Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally.
Cash and Cash Equivalents and Short Term Investments
Cash, Cash Equivalents and Short Term Investments

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value.

The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the
next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations.

Restricted Cash
In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the March 31, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 12 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 100 Euro at its Netherlands entity for potential Italian tenders.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.
The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.
Fair Value of Financial Instruments
Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.   

The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment
payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 4 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis.
Inventories, net
Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.
In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.
Property and Equipment, net
Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.
Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years
Amortizable Intangible Assets, net
Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses, including Band-Lok, the value of internally developed software, customer relationships, and non-competition agreements related to the acquisition of Orthex, and customer relationships and non-competition agreements related to the acquisitions of Telos and ApiFix. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period.
Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets.
Goodwill and Other Intangible Assets
Goodwill and Other Intangible Assets

Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No impairment charges were recorded in any of the periods presented.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof.
We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets.
Acquisition Payable and Contingent Consideration Acquisition Payable and Contingent ConsiderationUpon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations.
Cost of Revenue Cost of RevenueCost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.
Sales and Marketing Expenses Sales and Marketing ExpensesSales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.
Advertising Costs Advertising Costs Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.
Research and Development Costs Research and Development CostsResearch and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.
Stock-Based Compensation
Stock-Based Compensation

Prior to our Initial Public Offering ("IPO") in October 2017, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award.
Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.

Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.
Litigation and Contingencies Litigation and ContingenciesAccruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period.
Comprehensive Income (Loss) Comprehensive Income (Loss)Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments.
Income Taxes
Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance.
We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.
Leases
Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease.

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.
"Emerging Growth Company" and "Smaller Reporting Company" Reporting Requirements
“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

In October 2021, the FASB issued ASU No. 2021-08 "Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.

In May 2021, the FASB issued ASU No. 2021-04 "Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments". The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Schedule of Property and equipment, depreciable lives Sample inventory is carried at cost less accumulated depreciation. Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of goodwill Changes in the carrying amount of goodwill for the three months ended March 31, 2022 were as follows:
Total
Goodwill at January 1, 2022$72,349 
Foreign currency translation impact(1,362)
Goodwill at March 31, 2022
$70,987 
Schedule of finite-lived intangible assets
As of March 31, 2022, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.5 years$43,656 $(6,287)$37,369 
Intellectual Property9.8 years9,834 (1,584)8,250 
License Agreements5.2 years10,674 (2,817)7,857 
Total amortizable assets$64,164 $(10,688)$53,476 

As of December 31, 2021, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.7 years$44,493 $(5,664)$38,829 
Intellectual Property10.1 years9,847 (1408)8,439 
License Agreements5.5 years10,674 (2,448)8,226 
Total amortizable assets$65,014 $(9,520)$55,494 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of fair value, assets and liabilities measured on recurring basis The following table summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021.
March 31, 2022
Level 1Level 2Level 3Total
Financial Assets
Short term investments
Corporate Bonds$13,776 $— $— $13,776 
Treasury Bonds$7,445 $— $— $7,445 
Asset Backed Securities$— $5,261 $— $5,261 
Other$586 $— $— $586 
Financial Liabilities
Contingent Consideration$— $— $31,480 $31,480 
December 31, 2021
Level 1Level 2Level 3Total
Financial Assets
Short term investments
Corporate Bonds$22,476 $— $— $22,476 
Treasury Bonds$14,317 $— $— $14,317 
Asset Backed Securities$— $8,272 $— $8,272 
Other$837 $— $— $837 
Financial Liabilities
Contingent Consideration$— $— $28,910 $28,910 
Schedule of fair value, liabilities measured on recurring basis, unobservable input reconciliation The following table summarizes the change in fair value of Level 3 instruments in 2022:
Total
Balance at January 1, 2022
$28,910 
Change in fair value of contingent consideration2,570 
Balance at March 31, 2022
$31,480 
Schedule of fair value measurement inputs and valuation techniques
The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of March 31, 2022 and December 31, 2021:
March 31, 2022December 31, 2021
Valuation techniquesDiscounted cash flow, Monte Carlo
Present value discount rate(1)
19.3 %18.4 %
Volatility factor46.5 %50.3 %
Expected years2.1 years2.4 years

(1) The present value discount rate includes estimated risk premium.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.1
DEBT AND CREDIT ARRANGEMENTS (Tables)
 3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Schedule of long-term debt Long-term debt consisted of the following:
March 31, 2022December 31, 2021
Mortgage payable to affiliate$1,011 $1,044 
Less: current maturities139 137 
Long-term debt with affiliate, net of current maturities$872 $907 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of stock option activity Our stock option activity and related information are summarized as follows:
Weighted-AverageContractual Terms
OptionsExercise Price(in Years)
Outstanding at January 1, 20226,638 $30.97 1.3
Outstanding at March 31, 2022
6,638 $30.97 1.1
Schedule of restricted stock activity Our restricted stock activity and related information are summarized as follows:
Weighted-Average
Remaining
RestrictedContractual Terms
Stock(in Years)
Outstanding at January 1, 2022368,446 1.1
Granted146,425 
Forfeited(2,341)
Vested(120,656)
Outstanding at March 31, 2022
391,874 1.9
Restricted stock exercisable at March 31, 2022
— 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.1
NET LOSS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Schdule of reconciliation of basic and diluted net loss per share attributable to common stockholders The following is a reconciliation of basic and diluted net loss per share:
Three Months Ended
March 31,
20222021
Net loss$(9,100)$(10,379)
Weighted average number of shares - basic and diluted19,366,911 19,200,231 
Net loss per share - basic and diluted$(0.47)$(0.54)
Schedule of antidilutive securities excluded from computation of net loss per share The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented:
Three Months Ended March 31,
20222021
Restricted stock391,874 389,098 
Stock options6,638 10,792 
Total shares398,512 399,890 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS SEGMENT (Tables)
 3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Schedule of product sales by geographic location Product sales by source were as follows:
Three Months Ended March 31,
Product sales by geographic location:20222021
U.S.$18,188 $16,839 
International5,229 4,623 
Total$23,417 $21,462 
Schedule of product sales by category
Three Months Ended March 31,
Product sales by category:20222021
Trauma and deformity$16,516 $14,552 
Scoliosis5,983 5,951 
Sports medicine/other918 959 
Total$23,417 $21,462 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS (Details)
children in Thousands, $ in Millions
Mar. 31, 2022
USD ($)
children
Business Acquisition  
Impacted children | children 243
Estimated market portion opportunities $ 3,300
U.S.  
Business Acquisition  
Estimated market portion opportunities $ 1,500
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Accumulated deficit $ (187,126) $ (178,026)
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)
€ in Thousands, $ in Thousands
Mar. 31, 2022
USD ($)
Mar. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2019
USD ($)
Accounting Policies [Abstract]        
Escrow       $ 1,250
Restricted cash $ 1,363 € 100 $ 1,365  
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)
 3 Months Ended
Mar. 31, 2022
Building and building improvements | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 25 years
Building and building improvements | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 30 years
Furniture and fixtures | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Furniture and fixtures | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 7 years
Computer equipment | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 3 years
Computer equipment | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Business software  
Property, Plant and Equipment  
Depreciable lives (in years) 3 years
Office and other equipment | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Office and other equipment | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 7 years
Instruments  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Sample inventory  
Property, Plant and Equipment  
Depreciable lives (in years) 2 years
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Finite-Lived Intangible Assets    
Impairment charges, indefinite-lived $ 0 $ 0
Minimum    
Finite-Lived Intangible Assets    
Intangible asset, useful life (in years) 3 years  
Maximum    
Finite-Lived Intangible Assets    
Intangible asset, useful life (in years) 20 years  
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
reportingUnit
Mar. 31, 2021
USD ($)
Accounting Policies [Abstract]    
Impairment of indefinitely-lived tradename assets | $ $ 0 $ 0
Number of Reporting Units | reportingUnit 1  
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Accounting Policies [Abstract]    
Acquisition installment payable $ 453 $ 644
Fair value adjustment of contingent consideration $ 2,570 $ 4,150
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) - shares
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award      
Options granted (in shares) 0 0  
Stock option      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 3 years    
Options granted (in shares) 0 0  
Restricted stock      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 3 years    
Restricted stock | Vesting period one      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 6 years    
Restricted stock | Vesting period two      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 6 months    
Maximum | Stock option      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 3 years    
2007 Plan      
Share-based Compensation Arrangement by Share-based Payment Award      
Shares available for award (in shares)     1,585,000
2017 Plan      
Share-based Compensation Arrangement by Share-based Payment Award      
Shares available for award (in shares) 1,832,460    
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
USD ($)
Goodwill  
Goodwill, beginning balance $ 72,349
Foreign currency translation impact (1,362)
Goodwill, ending balance $ 70,987
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets, Net [Abstract]    
Gross Intangible Assets $ 64,164 $ 65,014
Accumulated Amortization (10,688) (9,520)
Net Intangible Assets $ 53,476 $ 55,494
Patents    
Finite-Lived Intangible Assets, Net [Abstract]    
Weighted-Average Amortization Period 13 years 6 months 13 years 8 months 12 days
Gross Intangible Assets $ 43,656 $ 44,493
Accumulated Amortization (6,287) (5,664)
Net Intangible Assets $ 37,369 $ 38,829
Intellectual Property    
Finite-Lived Intangible Assets, Net [Abstract]    
Weighted-Average Amortization Period 9 years 9 months 18 days 10 years 1 month 6 days
Gross Intangible Assets $ 9,834 $ 9,847
Accumulated Amortization (1,584) (1,408)
Net Intangible Assets $ 8,250 $ 8,439
License Agreements    
Finite-Lived Intangible Assets, Net [Abstract]    
Weighted-Average Amortization Period 5 years 2 months 12 days 5 years 6 months
Gross Intangible Assets $ 10,674 $ 10,674
Accumulated Amortization (2,817) (2,448)
Net Intangible Assets $ 7,857 $ 8,226
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Business Acquisition    
Other intangible assets $ 14,040 $ 14,268
Trademarks    
Business Acquisition    
Other intangible assets $ 14,040 $ 14,268
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent Consideration $ 31,480 $ 28,910
Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 13,776 22,476
Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 7,445 14,317
Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 5,261 8,272
Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 586 837
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent Consideration 0 0
Level 1 | Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 13,776 22,476
Level 1 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 7,445 14,317
Level 1 | Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 1 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 586 837
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent Consideration 0 0
Level 2 | Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 2 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 2 | Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 5,261 8,272
Level 2 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent Consideration 31,480 28,910
Level 3 | Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3 | Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments $ 0 $ 0
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Fair Value Disclosures [Abstract]    
Fair value adjustment of contingent consideration $ 2,570 $ 4,150
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) - Level 3 - Contingent Consideration Liability
$ in Thousands
 3 Months Ended
Mar. 31, 2022
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation  
Change in fair value of contingent consideration $ 2,570
Fair Value, Recurring  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation  
Contingent consideration, beginning balance 28,910
Contingent consideration, ending balance $ 31,480
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) - Level 3 - Fair Value, Recurring - Discounted cash flow, Monte Carlo
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Expected years 2 years 1 month 6 days 2 years 4 months 24 days
Present value discount rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent consideration, measurement input 19.30% 18.40%
Volatility factor    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent consideration, measurement input 46.50% 50.30%
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.1
DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) - Mortgage payable to affiliate - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Debt Instrument    
Total debt $ 1,011 $ 1,044
Less: current maturities 139 137
Long-term debt with affiliate, net of current maturities $ 872 $ 907
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.1
DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) - USD ($)
 3 Months Ended
Dec. 31, 2021
Aug. 04, 2020
Mar. 31, 2022
Mar. 31, 2021
Debt Instrument        
Interest expense, net     $ 566,000 $ 728,000
Mortgage payable to affiliate        
Debt Instrument        
Interest rate (as a percent)     5.00%  
Monthly interest and principal installments     $ 16,000  
Long-term debt $ 1,044,000   1,011,000  
Current portion of long-term debt with affiliate 137,000   139,000  
Note payable to Squadron        
Debt Instrument        
Interest expense, net     $ 13,000 $ 15,000
Revolving Credit Facility        
Debt Instrument        
Revolving credit facility $ 25,000      
Revolving Credit Facility | Third Amended Loan Agreement        
Debt Instrument        
Interest rate (as a percent) 10.00%      
Revolving Credit Facility | Third Amended Loan Agreement | Secured Overnight Financing Rate        
Debt Instrument        
Debt instrument, basis spread on variable rate (as a percent) 8.69%      
Revolving Credit Facility | Second Amended Loan Agreement        
Debt Instrument        
Interest rate (as a percent)   10.00%    
Unused commitment fee percentage (as a percent)   0.50%    
Revolving Credit Facility | Second Amended Loan Agreement | Three month LIBOR        
Debt Instrument        
Debt instrument, basis spread on variable rate (as a percent)   8.61%    
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 11, 2018
May 30, 2014
Income Tax Examination          
Income tax benefit $ 317 $ 312      
Effective income tax rate (as a percent) 3.40% 2.90%      
Loss carryforwards     $ 22,671    
Tax credit carryforward     176    
Estimated limitation on losses generated prior to ownership change date         $ 23,920
Estimated annual limitation of losses       $ 9,736 $ 1,062
Increase of estimated annual limitation of first five years       $ 22,430  
Federal and state          
Income Tax Examination          
Loss carryforwards     114,008    
State          
Income Tax Examination          
Loss carryforwards     $ 73,997    
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY - Stock Options (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award      
Options, granted (in shares) 0 0  
Stock option      
Share-based Compensation Arrangement by Share-based Payment Award      
Options, granted (in shares) 0 0  
Options      
Outstanding at period start (in shares) 6,638    
Outstanding at period end (in shares) 6,638   6,638
Weighted-Average Exercise Price      
Outstanding at period start, weighted-average exercise price (in dollars per share) $ 30.97    
Outstanding at period end, weighted-average exercise price (in dollars per share) $ 30.97   $ 30.97
Contractual terms (in years) 1 year 1 month 6 days   1 year 3 months 18 days
Vesting period (in years) 3 years    
Stock-based compensation expense $ 0 $ 0  
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY - Restricted Stock (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized      
Stock-based compensation $ 1,526 $ 1,316  
Restricted stock      
Restricted Stock      
Outstanding at period start (in shares) 368,446    
Granted (in shares) 146,425    
Forfeited (in shares) (2,341)    
Vested (in shares) (120,656)    
Outstanding at period end (in shares) 391,874   368,446
Weighted-average remaining contractual terms (in years) 1 year 10 months 24 days   1 year 1 month 6 days
Restricted stock exercisable (in shares) 0    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized      
Unrecognized compensation expense $ 12,443    
Unrecognized compensation expense, weighted average period of recognition (in years) 1 year 10 months 24 days    
Stock-based compensation $ 1,526 $ 1,440  
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.1
NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Earnings Per Share [Abstract]    
Net loss $ (9,100) $ (10,379)
Weighted average number of shares - basic (in shares) 19,366,911 19,200,231
Weighted average number of shares - diluted (in shares) 19,366,911 19,200,231
Net loss per share - basic (in dollars per share) $ (0.47) $ (0.54)
Net loss per share - diluted (in dollars per share) $ (0.47) $ (0.54)
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.1
NET LOSS PER SHARE - Antidilutive Securities (Details) - shares
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 398,512 399,890
Restricted stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 391,874 389,098
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 6,638 10,792
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS SEGMENT - Narrative (Details)
 3 Months Ended
Mar. 31, 2022
segment
Segment Reporting [Abstract]  
Number of operating segments 1
Number of reportable segments 1
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues from External Customers and Long-Lived Assets    
Net revenue $ 23,417 $ 21,462
U.S.    
Revenues from External Customers and Long-Lived Assets    
Net revenue 18,188 16,839
International    
Revenues from External Customers and Long-Lived Assets    
Net revenue $ 5,229 $ 4,623
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS SEGMENT - Schedule of Revenue by Category (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Segment Reporting Information    
Net revenue $ 23,417 $ 21,462
Trauma and deformity    
Segment Reporting Information    
Net revenue 16,516 14,552
Scoliosis    
Segment Reporting Information    
Net revenue 5,983 5,951
Sports medicine/other    
Segment Reporting Information    
Net revenue $ 918 $ 959
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Details) - Affiliated Entity
$ in Thousands
 3 Months Ended
Mar. 31, 2022
USD ($)
supplier
Mar. 31, 2021
USD ($)
Dec. 31, 2019
USD ($)
Related Party Transaction      
Number of related party suppliers | supplier 1    
Discontinued Operations, Disposed of by Sale      
Related Party Transaction      
Divestiture purchase price     $ 25,000
Structure Medical, LLC      
Related Party Transaction      
Payments to related party $ 316 $ 72  
Vilex      
Related Party Transaction      
Payments to related party 25 189  
Sales to related party $ 8 $ 87  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.1
EMPLOYEE BENEFIT PLAN - Narrative (Details)
 3 Months Ended
Mar. 31, 2022
Retirement Benefits [Abstract]  
Employer contribution as a percentage of employees' salary (as a percent) 4.00%
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jul. 20, 2021
Dec. 31, 2019
Jun. 30, 2019
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Long-term Purchase Commitment            
Operating lease liability       $ 241,000    
Operating lease right-of-use asset       $ 243,000    
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]           Other long-term liabilities
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]       Assets, Noncurrent, Excluding Property, Plant and Equipment    
Purchase commitment, remaining minimum amount committed       $ 1,900,000    
Cost of revenue       $ 4,851,000 $ 5,137,000  
Minimum            
Long-term Purchase Commitment            
Royalty agreement percentage (as a percent)       0.50%    
Maximum            
Long-term Purchase Commitment            
Royalty agreement percentage (as a percent)       20.00%    
License Agreements | Firefly Technology            
Long-term Purchase Commitment            
Finite lived intangible asset useful life extension period (in years) 5 years          
Cost of revenue       $ 101,000    
Legal settlement expense         $ 0  
Squadron | Team note B | Affiliated Entity            
Long-term Purchase Commitment            
Payments on note with affiliate   $ 25,000,000        
Vilex and Orthex            
Long-term Purchase Commitment            
Business Combination, Consideration Transferred     $ 60,000,000      
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS (Details) - USD ($)
$ / shares in Units, $ in Thousands
Apr. 01, 2022
Mar. 31, 2022
Dec. 31, 2021
Subsequent Event [Line Items]      
Common stock, par value (in dollars per share)   $ 0.00025 $ 0.00025
Subsequent Event | Mitchell Designs, Inc      
Subsequent Event [Line Items]      
Cash consideration $ 8,200    
Consideration for acquisition (in shares) 173,241    
Common stock, par value (in dollars per share) $ 0.00025    
Issuance of common stock $ 9,707    
Common stock (in dollars per share) $ 56.03    
Subsequent Event | ApiFix Ltd      
Subsequent Event [Line Items]      
Cash consideration $ 3,233    
Consideration for acquisition (in shares) 185,811    
Issuance of common stock $ 10,411    
Common stock (in dollars per share) $ 56.03    
XML 72 kids-20220331_htm.xml IDEA: XBRL DOCUMENT 0001425450 2022-01-01 2022-03-31 0001425450 2022-05-03 0001425450 2022-03-31 0001425450 2021-12-31 0001425450 2021-01-01 2021-03-31 0001425450 us-gaap:CommonStockMember 2021-12-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001425450 us-gaap:RetainedEarningsMember 2021-12-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001425450 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001425450 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001425450 us-gaap:CommonStockMember 2022-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001425450 us-gaap:RetainedEarningsMember 2022-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001425450 us-gaap:CommonStockMember 2020-12-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001425450 us-gaap:RetainedEarningsMember 2020-12-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001425450 2020-12-31 0001425450 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001425450 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001425450 us-gaap:CommonStockMember 2021-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001425450 us-gaap:RetainedEarningsMember 2021-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001425450 2021-03-31 0001425450 country:US 2022-03-31 0001425450 2019-12-31 0001425450 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-03-31 0001425450 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-03-31 0001425450 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0001425450 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0001425450 srt:MinimumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0001425450 srt:MaximumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0001425450 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-01 2022-03-31 0001425450 srt:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-03-31 0001425450 srt:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-03-31 0001425450 us-gaap:TechnologyEquipmentMember 2022-01-01 2022-03-31 0001425450 kids:SampleInventoryMember 2022-01-01 2022-03-31 0001425450 srt:MinimumMember 2022-01-01 2022-03-31 0001425450 srt:MaximumMember 2022-01-01 2022-03-31 0001425450 kids:A2007EquityIncentivePlanMember 2017-09-30 0001425450 kids:New2017EquityIncentivePlanMember 2022-03-31 0001425450 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001425450 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001425450 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-01-01 2022-03-31 0001425450 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-01-01 2022-03-31 0001425450 us-gaap:PatentsMember 2022-01-01 2022-03-31 0001425450 us-gaap:PatentsMember 2022-03-31 0001425450 us-gaap:IntellectualPropertyMember 2022-01-01 2022-03-31 0001425450 us-gaap:IntellectualPropertyMember 2022-03-31 0001425450 us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0001425450 us-gaap:LicensingAgreementsMember 2022-03-31 0001425450 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001425450 us-gaap:PatentsMember 2021-12-31 0001425450 us-gaap:IntellectualPropertyMember 2021-01-01 2021-12-31 0001425450 us-gaap:IntellectualPropertyMember 2021-12-31 0001425450 us-gaap:LicensingAgreementsMember 2021-01-01 2021-12-31 0001425450 us-gaap:LicensingAgreementsMember 2021-12-31 0001425450 us-gaap:TrademarksMember 2022-03-31 0001425450 us-gaap:TrademarksMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member kids:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member kids:ContingentConsiderationLiabilityMember 2022-01-01 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member kids:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-01-01 2021-12-31 0001425450 us-gaap:MortgagesMember 2022-03-31 0001425450 us-gaap:MortgagesMember 2021-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:ThirdAmendedLoanAgreementMember kids:SecuredOvernightFinancingRateMember 2021-12-31 2021-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:ThirdAmendedLoanAgreementMember 2021-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:SecondAmendedLoanAgreementMember 2020-08-04 2020-08-04 0001425450 us-gaap:RevolvingCreditFacilityMember kids:SecondAmendedLoanAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-04 2020-08-04 0001425450 us-gaap:RevolvingCreditFacilityMember kids:SecondAmendedLoanAgreementMember 2020-08-04 0001425450 us-gaap:MortgagesMember 2022-01-01 2022-03-31 0001425450 us-gaap:NotesPayableOtherPayablesMember 2022-01-01 2022-03-31 0001425450 us-gaap:NotesPayableOtherPayablesMember 2021-01-01 2021-03-31 0001425450 us-gaap:DomesticCountryMember 2021-12-31 0001425450 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001425450 2014-05-30 0001425450 2018-12-11 0001425450 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001425450 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001425450 us-gaap:EmployeeStockOptionMember 2021-12-31 0001425450 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001425450 us-gaap:EmployeeStockOptionMember 2022-03-31 0001425450 us-gaap:RestrictedStockMember 2021-12-31 0001425450 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001425450 us-gaap:RestrictedStockMember 2022-03-31 0001425450 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001425450 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001425450 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001425450 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001425450 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001425450 country:US 2022-01-01 2022-03-31 0001425450 country:US 2021-01-01 2021-03-31 0001425450 us-gaap:NonUsMember 2022-01-01 2022-03-31 0001425450 us-gaap:NonUsMember 2021-01-01 2021-03-31 0001425450 kids:TraumaAndDeformityMember 2022-01-01 2022-03-31 0001425450 kids:TraumaAndDeformityMember 2021-01-01 2021-03-31 0001425450 kids:SpineMember 2022-01-01 2022-03-31 0001425450 kids:SpineMember 2021-01-01 2021-03-31 0001425450 kids:SportsMedicineAndOtherMember 2022-01-01 2022-03-31 0001425450 kids:SportsMedicineAndOtherMember 2021-01-01 2021-03-31 0001425450 srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001425450 kids:StructureMedicalLLCMember srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001425450 kids:StructureMedicalLLCMember srt:AffiliatedEntityMember 2021-01-01 2021-03-31 0001425450 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember srt:AffiliatedEntityMember 2019-12-31 0001425450 kids:VilexMember srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001425450 kids:VilexMember srt:AffiliatedEntityMember 2021-01-01 2021-03-31 0001425450 kids:VilexAndOrthexMember 2019-06-01 2019-06-30 0001425450 kids:SquadronMember kids:TeamNoteBMember srt:AffiliatedEntityMember 2019-12-31 2019-12-31 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2021-07-20 2021-07-20 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-03-31 0001425450 kids:MitchellDesignsIncMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-01 0001425450 kids:MitchellDesignsIncMember us-gaap:SubsequentEventMember 2022-04-01 0001425450 kids:ApiFixLtdMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-01 0001425450 kids:ApiFixLtdMember us-gaap:SubsequentEventMember 2022-04-01 shares iso4217:USD iso4217:USD shares kids:children iso4217:EUR kids:reportingUnit pure kids:segment kids:supplier 2022 Q1 false 0001425450 --12-31 http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://www.orthopediatrics.com/20220331#AssetsNoncurrentExcludingPropertyPlantAndEquipment http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://www.orthopediatrics.com/20220331#AssetsNoncurrentExcludingPropertyPlantAndEquipment 10-Q true 2022-03-31 false 001-38242 OrthoPediatrics Corp DE 26-1761833 2850 Frontier Drive Warsaw IN 46582 574 268-6379 Common Stock, $0.00025 par value per share KIDS NASDAQ Yes Yes Non-accelerated Filer true true true false 20229901 17957000 7641000 1363000 1365000 27068000 45902000 357000 347000 17911000 17942000 64077000 57569000 3048000 3229000 131424000 133648000 31068000 28515000 53476000 55494000 70987000 72349000 14040000 14268000 138503000 142111000 300995000 304274000 14578000 9325000 4433000 5351000 139000 137000 12934000 12862000 2249000 2040000 34333000 29715000 872000 907000 14690000 14309000 31480000 28910000 4335000 4771000 241000 293000 51618000 49190000 85951000 78905000 0.00025 0.00025 50000000 50000000 19821298 19821298 19677214 19677214 5000 5000 396425000 394899000 -187126000 -178026000 5740000 8491000 215044000 225369000 300995000 304274000 23417000 21462000 4851000 5137000 18566000 16325000 9758000 8949000 13167000 12041000 2027000 1308000 24952000 22298000 -6386000 -5973000 -566000 -728000 2570000 4150000 105000 160000 -3031000 -4718000 -9417000 -10691000 -317000 -312000 -9100000 -10379000 19366911 19366911 19200231 19200231 -0.47 -0.47 -0.54 -0.54 -9100000 -10379000 -2198000 -3499000 -553000 -123000 -2751000 -3622000 -11851000 -14001000 19677214 5000 394899000 -178026000 8491000 225369000 -9100000 -9100000 -2751000 -2751000 144084 1526000 1526000 19821298 5000 396425000 -187126000 5740000 215044000 19560291 5000 388622000 -161766000 7907000 234768000 -10379000 -10379000 -3622000 -3622000 2010 62000 62000 97111 1316000 1316000 19659412 5000 390000000 -172145000 4285000 222145000 -9100000 -10379000 2961000 2539000 1526000 1316000 2570000 4150000 453000 644000 317000 312000 -2000 -653000 6750000 2508000 -112000 -708000 5258000 2058000 0 1092000 -690000 446000 222000 138000 -4197000 -1915000 18500000 0 0 2858000 4197000 2749000 14303000 -5607000 0 62000 33000 32000 -33000 30000 241000 155000 10314000 -7337000 9006000 30132000 19320000 22795000 13000 15000 -54000 57000 BUSINESS<div style="padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Spine, BandLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Pediatric Nailing Platform | Femur, Orthex, QuickPack</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> and ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div style="padding-right:8pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 243,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300 opportunity globally, including over $1,500 in the United States.</span></div><div style="padding-right:5pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">Our largest investor is Squadron, a private investment firm based in Granby, Connecticut. </span></div>A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. As a result of the pandemic, we have experienced significant business disruption. For example, in preparation for COVID-19-related hospitalizations, various governments, governmental agencies and hospital administrators required certain hospitals to postpone some elective procedures. As a majority of our products are utilized in elective surgeries or procedures, the deferrals of such surgeries and procedures have had, and may continue to have, a significant negative impact on our business and results of operations. Despite the impact COVID-19 has had on our business, we continued to invest in research and development, invest in our people, and take steps to position ourselves for long-term success. We continue to train and educate our sales team and our surgeons on our products. We have continued to focus on developing innovative solutions, acquired multiple enabling technologies, invested in both new and existing partnerships and continued to deploy additional consigned instrument and implant sets in furtherance of our strategy. The extent to which COVID-19 may continue to negatively impact the Company's consolidated financial position, results of operations or cash flows is uncertain and will be closely monitored. 243000 3300000000 1500000000 SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V., </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orthex, LLC, Telos Partners, LLC and ApiFix, Ltd. (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2022 and 2021 and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div><div style="padding-left:1pt;padding-right:1pt"><span><br/></span></div><div style="padding-left:1pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $187,126 and $178,026 as of March 31, 2022 and December 31, 2021, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short term investments, at March 31, 2022 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months. </span></div><div style="padding-left:1pt;padding-right:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland, </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Contracts with Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – United States</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – International</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns. </span><span style="color:#226600;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when title passes upon shipment. Pricing for each customer is dictated by a unique pricing agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Short Term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the March 31, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 12 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 100 Euro at its Netherlands entity for potential Italian tenders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.</span></div><div><span><br/></span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 4 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciable lives are generally as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 to 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sample inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortizable Intangible Assets, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include fees necessary to secure various patents and licenses, including Band-Lok, the value of internally developed software, customer relationships, and non-competition agreements related to the acquisition of Orthex, and customer relationships and non-competition agreements related to the acquisitions of Telos and ApiFix. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges were recorded in any of the periods presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No impairment charges were recorded in any of the periods presented. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. No impairment charges were recorded in any of the periods presented. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition Payable and Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. The amount of expense related to acquisition installment payables recorded in interest expense, net for the three months ended March 31, 2022 and March 31, 2021 were $453 and $644, respectively. The fair value adjustments of contingent consideration for the three months ended March 31, 2022 and March 31, 2021 were expense adjustments of $2,570 and $4,150, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our Initial Public Offering ("IPO") in October 2017, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers".</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments"</span>. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V., </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orthex, LLC, Telos Partners, LLC and ApiFix, Ltd. (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2022 and 2021 and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div>The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. -187126000 -178026000 Use of EstimatesPreparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland, </span></div>Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Contracts with Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – United States</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – International</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns. </span><span style="color:#226600;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Beginning in early 2017 and continuing through 2021, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Short Term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div>In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the March 31, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 12 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 100 Euro at its Netherlands entity for potential Italian tenders. 1250000 100000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.</span></div>The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.</span></div><div><span><br/></span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment </span></div>payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 4 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle. </span></div>In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciable lives are generally as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 to 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sample inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></div></td></tr></table> Sample inventory is carried at cost less accumulated depreciation. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciable lives are generally as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 to 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sample inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></div></td></tr></table> P25Y P30Y P5Y P7Y P3Y P5Y P3Y P5Y P7Y P5Y P2Y <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortizable Intangible Assets, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include fees necessary to secure various patents and licenses, including Band-Lok, the value of internally developed software, customer relationships, and non-competition agreements related to the acquisition of Orthex, and customer relationships and non-competition agreements related to the acquisitions of Telos and ApiFix. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period. </span></div>Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. P3Y P20Y 0 0 0 0 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No impairment charges were recorded in any of the periods presented. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof. </span></div>We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the assets. 0 0 0 0 1 0 0 0 0 Acquisition Payable and Contingent ConsiderationUpon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. 453000 644000 2570000 4150000 Cost of RevenueCost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States. Sales and Marketing ExpensesSales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors. Advertising Costs Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense. Research and Development CostsResearch and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our Initial Public Offering ("IPO") in October 2017, we maintained an Amended and Restated 2007 Equity Incentive Plan (the “2007 Plan”) that provided for grants of options and restricted stock to employees, directors and associated third-party representatives of the Company as determined by the Board of Directors. The 2007 Plan had authorized 1,585,000 shares for award. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan") which replaced the 2007 Plan. The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.</span></div> 1585000 1832460 P3Y 0 0 P3Y P6Y P6M Litigation and ContingenciesAccruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period. Comprehensive Income (Loss)Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance. </span></div>We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </span></div>We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers".</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments"</span>. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures. GOODWILL AND INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill for the three months ended March 31, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the balances of amortizable intangible assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,287)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,164 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,688)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,476 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the balances of amortizable intangible assets were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,664)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,520)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses are tied to product launches and do not begin amortizing until the product is launched to the market. </span></div>Trademarks are non-amortizing intangible assets which were $14,040 and $14,268 as of March 31, 2022 and December 31, 2021, respectively. Trademarks are recorded in Other Intangible assets on the condensed consolidated balance sheets. The change in balance during the three months ended March 31, 2022 was the result of foreign currency translation of the ApiFix trademark. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill for the three months ended March 31, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 72349000 -1362000 70987000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the balances of amortizable intangible assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,287)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,164 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,688)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,476 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the balances of amortizable intangible assets were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,664)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,520)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P13Y6M 43656000 6287000 37369000 P9Y9M18D 9834000 1584000 8250000 P5Y2M12D 10674000 2817000 7857000 64164000 10688000 53476000 P13Y8M12D 44493000 5664000 38829000 P10Y1M6D 9847000 1408000 8439000 P5Y6M 10674000 2448000 8226000 65014000 9520000 55494000 14040000 14268000 FAIR VALUE OF FINANCIAL INSTRUMENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.</span></div><div><span><br/></span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.</span></div><div style="padding-left:14pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's level 1 assets consist of cash equivalents which are generally comprised of short-term, liquid investments with original maturity of three months or less at inception and other short term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date using an option pricing model and a Monte Carlo simulation based on forecasted annual revenue, expected volatility and discount rates. The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement. The adjustments in the fair value of the contingent consideration payments included expense adjustment of $2,570 and $4,150 for the three month periods ended March 31, 2022 and March 31, 2021, respectively, in other expenses on the condensed consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The following table summarizes the change in fair value of Level 3 instruments in 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,480 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of March 31, 2022 and December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation techniques</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow, Monte Carlo</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value discount rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4 years</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The present value discount rate includes estimated risk premium.</span></div>The estimated fair value reflects assumptions made by management as of March 31, 2022; however, the actual amount ultimately paid could be higher or lower than the fair value of the remaining contingent consideration. The following table summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 13776000 0 0 13776000 7445000 0 0 7445000 0 5261000 0 5261000 586000 0 0 586000 0 0 31480000 31480000 22476000 0 0 22476000 14317000 0 0 14317000 0 8272000 0 8272000 837000 0 0 837000 0 0 28910000 28910000 2570000 4150000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The following table summarizes the change in fair value of Level 3 instruments in 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,480 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 28910000 2570000 31480000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of March 31, 2022 and December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation techniques</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow, Monte Carlo</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value discount rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4 years</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The present value discount rate includes estimated risk premium.</span></div> 0.193 0.184 0.465 0.503 P2Y1M6D P2Y4M24D DEBT AND CREDIT ARRANGEMENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:57.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage payable to affiliate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt with affiliate, net of current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2021, the Company entered into a Third Amendment (the "Third Amendment") to its Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC, or Squadron (as so amended, the “Loan Agreement”). The Loan Agreement provides a $25,000 revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears. Prior to the Third Amendment, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. While the Loan Agreement previously provided for certain term loans, there are no longer any outstanding term loan obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the revolving credit facility are made under a First Amended and Restated Revolving Note, dated August 4, 2020 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024. </span></div><div><span><br/></span></div><div style="padding-right:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions. </span></div>In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At March 31, 2022 the mortgage balance was $1,011 of which current principal of $139 was included in the current portion of long-term debt. As of December 31, 2021, the mortgage balance was $1,044 of which current principal due of $137 was included in the current portion of long-term debt. The aggregate interest expense relating to the notes payable to Squadron and the mortgage note payable to Tawani was $13 and $15 for the three months ended March 31, 2022 and 2021, respectively. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:57.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage payable to affiliate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt with affiliate, net of current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1011000 1044000 139000 137000 872000 907000 25000 0.0869 0.10 0.005 0.0861 0.10 16000 0.05 1011000 139000 1044000 137000 -13000 -15000 INCOME TAXES <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, the income tax benefit was $317 compared to $312 for the three months ended March 31, 2021. Our effective income tax rate was 3.4% and 2.9% for the three months ended March 31, 2022 and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets were fully offset by a valuation allowance at March 31, 2022 and December 31, 2021, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix. The company has recorded a tax benefit during the period ended March 31, 2022 for losses generated in the foreign jurisdiction. As of December 31, 2021, we had available federal, state and foreign tax loss carryforwards of $114,008, $73,997 and $22,671, respectively. We had available federal tax credits of $176. Net operating losses generated prior to December 31, 2017 will begin to expire in 2028. Federal net operating losses generated after January 1, 2018 will have an indefinite carryforward period. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $23,920 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062. A second ownership change under Section 382 was deemed to occur on December 11, 2018. The estimated annual limitation is $9,736, which is increased by $22,430 annually over the first five years as a result of an unrealized built in gain. NOLs sustained prior to May 30, 2014 will still be constrained by the lower limitation. </span></div>Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended March 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. -317000 -312000 0.034 0.029 114008000 73997000 22671000 176000 23920000 1062000 9736000 22430000 STOCKHOLDERS’ EQUITY<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock option activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options generally include a time-based vesting schedule permitting the options to vest ratably over three years. At March 31, 2022 and December 31, 2021, all options were fully vested. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no stock-based compensation expense on stock options for the three months ended March 31, 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,425 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120,656)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock exercisable at March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022, there was $12,443 of unrecognized compensation expense remaining related to our service-based restricted stock awards. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 1.9 years or earlier upon an elimination of the restriction period as a result of a change in control event. </span></div>Stock-based compensation expense on restricted stock amounted to $1,526 and $1,440 for the three months ended March 31, 2022 and 2021, respectively. The increase in the stock compensation for the three months ended March 31, 2022 is primarily due to increase in plan participants as we continue to hire employees to support the continued expansion of our business. 0 0 0 0 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock option activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td></tr></table> 6638 30.97 P1Y3M18D 6638 30.97 P1Y1M6D P3Y 0 0 0 0 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,425 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120,656)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock exercisable at March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table> 368446 P1Y1M6D 146425 2341 120656 391874 P1Y10M24D 0 12443000 P1Y10M24D 1526000 1440000 NET LOSS PER SHARE<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted net loss per share:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.440%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,366,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,200,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our basic and diluted net loss per share is computed using the two-class method.  The two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have incurred a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share. The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,512 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,890 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted net loss per share:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.440%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,366,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,200,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -9100000 -10379000 19366911 19366911 19200231 19200231 -0.47 -0.47 -0.54 -0.54 The following contingently issuable and convertible equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,512 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,890 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 391874 389098 6638 10792 398512 399890 BUSINESS SEGMENT <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No customers accounted for more than 10% of total product sales for the three months ended March 31, 2022 or 2021. No customer accounted for more than 10% of consolidated accounts receivable as of March 31, 2022 and December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by source were as follows: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by geographic location:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,623 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,462 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.025%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by category:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trauma and deformity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scoliosis</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,983 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,951 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sports medicine/other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,417 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,462 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three months ended March 31, 2022 and 2021. 1 1 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by source were as follows: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by geographic location:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,623 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,462 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 18188000 16839000 5229000 4623000 23417000 21462000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by category:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trauma and deformity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scoliosis</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,983 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,951 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sports medicine/other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,417 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,462 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 16516000 14552000 5983000 5951000 918000 959000 23417000 21462000 RELATED PARTY TRANSACTIONSIn addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $316 and $72 for the three months ended March 31, 2022 and 2021, respectively.On December 31, 2019, the Company divested Vilex for $25,000 to an affiliate of Squadron. In conjunction with the divestiture, the Company also entered into an exclusive perpetual license agreement to permit the purchasers of Vilex the ability to access intellectual property and sell products using the external fixation technology of Orthex, LLC to non-pediatric accounts. We had sales and payments related to inventory purchases to Squadron's affiliate, now known as Vilex, LLC, of $8 and $25, respectively, for the three months ended March 31, 2022. We had sales and payments related to inventory purchases to Vilex, LLC of $87 and $189, respectively, for the three months ended March 31, 2021 1 316000 72000 25000000 8000 25000 87000 189000 EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary. 0.04 COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2022, the Company has recorded a lease liability of $241 and corresponding right-of-use-asset of $243 on its <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlZDk4NTJjMjQ5ZTRhYTJiNTRhNjg0ZDhkZDFlMzZhL3NlYzplZWQ5ODUyYzI0OWU0YWEyYjU0YTY4NGQ4ZGQxZTM2YV83Ni9mcmFnOmI0OTYwYzBkM2FkOTQ0ZTViMTljZGUzZjI0MDRkZTdlL3RleHRyZWdpb246YjQ5NjBjMGQzYWQ5NDRlNWIxOWNkZTNmMjQwNGRlN2VfNDM5ODA0NjUyMDc0Mw_1ee6a3b2-396c-4929-9033-9dd75c4d2c34"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlZDk4NTJjMjQ5ZTRhYTJiNTRhNjg0ZDhkZDFlMzZhL3NlYzplZWQ5ODUyYzI0OWU0YWEyYjU0YTY4NGQ4ZGQxZTM2YV83Ni9mcmFnOmI0OTYwYzBkM2FkOTQ0ZTViMTljZGUzZjI0MDRkZTdlL3RleHRyZWdpb246YjQ5NjBjMGQzYWQ5NDRlNWIxOWNkZTNmMjQwNGRlN2VfNDM5ODA0NjUyMDc0Mw_210d4247-b26f-41bc-8d86-b947404df91a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlZDk4NTJjMjQ5ZTRhYTJiNTRhNjg0ZDhkZDFlMzZhL3NlYzplZWQ5ODUyYzI0OWU0YWEyYjU0YTY4NGQ4ZGQxZTM2YV83Ni9mcmFnOmI0OTYwYzBkM2FkOTQ0ZTViMTljZGUzZjI0MDRkZTdlL3RleHRyZWdpb246YjQ5NjBjMGQzYWQ5NDRlNWIxOWNkZTNmMjQwNGRlN2VfNDM5ODA0NjUyMDc0Mw_9eea6085-4a62-45a9-98b9-d935d5cf25fb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlZDk4NTJjMjQ5ZTRhYTJiNTRhNjg0ZDhkZDFlMzZhL3NlYzplZWQ5ODUyYzI0OWU0YWEyYjU0YTY4NGQ4ZGQxZTM2YV83Ni9mcmFnOmI0OTYwYzBkM2FkOTQ0ZTViMTljZGUzZjI0MDRkZTdlL3RleHRyZWdpb246YjQ5NjBjMGQzYWQ5NDRlNWIxOWNkZTNmMjQwNGRlN2VfNDM5ODA0NjUyMDc0Mw_feaeaec5-95e1-4abc-9731-c7747b1ad672">condensed consolidated balance sheet</span></span></span></span>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">IMED Surgical - Software Ownership Dispute</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron Capital, LLC (“Squadron”), and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company (the “Plaintiff”), in Broward County, Florida Circuit Court. In the lawsuit, the Plaintiff claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point &amp; Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with the Plaintiff.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plaintiff, among other things, requests that the defendants be ordered to convey and assign to Plaintiff all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent the Plaintiff desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, the Plaintiff initiated an arbitration proceeding. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to the Plaintiff before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the IMED lawsuit is without merit and will vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Wishbone Medical, Inc. – Patent Infringement Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2020, OrthoPediatrics, along with its wholly-owned subsidiary, Orthex, LLC, filed a lawsuit in federal district court (N.D. Indiana, South Bend Division, Case No. 3:20-cv-00929) against Wishbone Medical, Inc. and Nick A. Deeter (collectively “Wishbone”), claiming infringement of ’377 Patent, unfair competition, false advertising, breach of contract, defamation per se, tortious interference with contractual relationships, and tortious interference with prospective contractual relationships. In early January 2021, OrthoPediatrics amended its lawsuit by adding a declaratory judgment claim of infringement of the ‘377 Patent against Wishbone. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter, in January 2021, Wishbone filed a motion to dismiss all OrthoPediatrics’ causes of action. In late August 2021, the Court denied Wishbone's motion to dismiss with respect to OrthoPediatrics’ infringement and breach of contract claims and dismissed OrthoPediatrics' remaining causes of action. In late September 2021, Wishbone filed its answer and counterclaims, in part, seeking declaratory judgment of non-infringement and invalidity of the ‘377 Patent, and alleging OrthoPediatrics patent infringement claim(s) against Wishbone was made in bad faith. In mid-October 2021, OrthoPediatrics filed its answer to Wishbone’s counterclaims, denying all of them. Although we believe Wishbone’s counterclaims are without merit and will vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have an adverse effect on our business, operating results and financial condition.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Purchase Obligations and Performance Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASH</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Navigation platform, the Company has agreed to a minimum purchase commitment for the first twelve months of that agreement. As of March 31, 2022, the remaining purchase commitment under the agreement was $1,900.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three months ended March 31, 2022, the Company recorded an expense of $101 based on current estimates. No expense was recorded for the three months ended March 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales. </span></div>We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of March 31, 2022, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results. 241000 243000 60000000 25000000 1900000 P5Y 101000 0 0.005 0.20 SUBSEQUENT EVENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MD Orthopaedics Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with OrthoPediatrics Iowa Holdco, Inc., a Delaware corporation and newly-formed wholly-owned subsidiary of the Company (“Merger Sub”), Mitchell Designs, Inc. (“Designs”), an Iowa corporation and the sole shareholder of MD Orthopaedics, Inc., also an Iowa corporation (“MD Ortho”) and John Mitchell, the sole shareholder of Designs (“Mitchell”). MD Ortho has developed and manufactures a portfolio of orthopedic clubfoot products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Designs merged with and into Merger Sub effective April 1, 2022. Under the terms of the Merger Agreement, the Company paid to Mitchell consideration of (a) $8,200 in cash, and (b) 173,241 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $9,707 (based on the April 1, 2022 closing share price of $56.03).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApiFix Acquisition Installment Payment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, the second-year anniversary of the acquisition of ApiFix, the Company paid $3,233 in cash and issued 185,811 shares of the Company's common stock, representing $10,411 of fair value (based on the April 1, 2022 closing share price of $56.03), to fulfill its installment obligation to ApiFix. This was the first installment payment paid since the acquisition.</span></div> 8200000 173241 0.00025 9707000 56.03 3233000 185811 10411000 56.03 EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO=V]R:W-H965T&UL4$L! A0#% @ M*(.E5 :!MP74 @ G@8 !D ("!7-8 'AL+W=O MX >&PO=V]R:W-H965T&UL4$L! A0#% @ *(.E5"$GD N0 @ X04 !D M ("!G^< 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ *(.E5(;E+CAD @ >04 !D ("!"_$ 'AL M+W=OG"HTH$ M #L$0 &0 @(&F\P >&PO=V]R:W-H965T&UL4$L! A0#% @ *(.E M5/O',ZTG!0 L"( !D ("!H/H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *(.E5.?&'@L3 P KPD M !D ("!E04! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *(.E5(C6IQ&@ P = P !D M ("!$1 ! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ *(.E5":_M WW @ 9 @ !D ("!Y1L! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ *(.E5-EU M>8_" @ !@@ !D ("!8R0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *(.E5 Z?K\DH @ F 0 !D M ("!YBT! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ *(.E5#L*7JXD P CA$ T ( ! MQS@! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L! A0#% @ *(.E5/,@BWGI 0 $B( !H ( !Q$$! M 'AL+U]R96QS+W=O XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 168 236 1 false 63 0 false 9 false false R1.htm 0001001 - Document - Cover Sheet http://www.orthopediatrics.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - BUSINESS Sheet http://www.orthopediatrics.com/role/BUSINESS BUSINESS Notes 8 false false R9.htm 2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2113103 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 10 false false R11.htm 2118104 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 11 false false R12.htm 2124105 - Disclosure - DEBT AND CREDIT ARRANGEMENTS Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS Notes 12 false false R13.htm 2128106 - Disclosure - INCOME TAXES Sheet http://www.orthopediatrics.com/role/INCOMETAXES INCOME TAXES Notes 13 false false R14.htm 2130107 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 2134108 - Disclosure - NET LOSS PER SHARE Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 15 false false R16.htm 2138109 - Disclosure - BUSINESS SEGMENT Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENT BUSINESS SEGMENT Notes 16 false false R17.htm 2143110 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 2145111 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN EMPLOYEE BENEFIT PLAN Notes 18 false false R19.htm 2147112 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 2149113 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.orthopediatrics.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 20 false false R21.htm 2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES 22 false false R23.htm 2314302 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS 23 false false R24.htm 2319303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS 24 false false R25.htm 2325304 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables DEBT AND CREDIT ARRANGEMENTS (Tables) Tables http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS 25 false false R26.htm 2331305 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY 26 false false R27.htm 2335306 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.orthopediatrics.com/role/NETLOSSPERSHARE 27 false false R28.htm 2339307 - Disclosure - BUSINESS SEGMENT (Tables) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables BUSINESS SEGMENT (Tables) Tables http://www.orthopediatrics.com/role/BUSINESSSEGMENT 28 false false R29.htm 2402401 - Disclosure - BUSINESS (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSDetails BUSINESS (Details) Details http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables 29 false false R30.htm 2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) Details 30 false false R31.htm 2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Details 31 false false R32.htm 2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) Details 32 false false R33.htm 2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) Details 33 false false R34.htm 2410406 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) Details 34 false false R35.htm 2411407 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) Details 35 false false R36.htm 2412408 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) Details 36 false false R37.htm 2415409 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) Details 37 false false R38.htm 2416410 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) Details 38 false false R39.htm 2417411 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 39 false false R40.htm 2420412 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) Details 40 false false R41.htm 2421413 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables 41 false false R42.htm 2422414 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) Details 42 false false R43.htm 2423415 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) Details 43 false false R44.htm 2426416 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Details 44 false false R45.htm 2427417 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Details 45 false false R46.htm 2429418 - Disclosure - INCOME TAXES (Details) Sheet http://www.orthopediatrics.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.orthopediatrics.com/role/INCOMETAXES 46 false false R47.htm 2432419 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails STOCKHOLDERS' EQUITY - Stock Options (Details) Details 47 false false R48.htm 2433420 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails STOCKHOLDERS' EQUITY - Restricted Stock (Details) Details 48 false false R49.htm 2436421 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) Details 49 false false R50.htm 2437422 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails NET LOSS PER SHARE - Antidilutive Securities (Details) Details 50 false false R51.htm 2440423 - Disclosure - BUSINESS SEGMENT - Narrative (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails BUSINESS SEGMENT - Narrative (Details) Details 51 false false R52.htm 2441424 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Details 52 false false R53.htm 2442425 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Details 53 false false R54.htm 2444426 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS 54 false false R55.htm 2446427 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails EMPLOYEE BENEFIT PLAN - Narrative (Details) Details 55 false false R56.htm 2448428 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES 56 false false R57.htm 2450429 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.orthopediatrics.com/role/SUBSEQUENTEVENTS 57 false false All Reports Book All Reports kids-20220331.htm exhibit311-ceocertificatio.htm exhibit312-cfocertificatio.htm exhibit321-ceocertificatio.htm exhibit322-cfocertificatio.htm hauserjoe2022employmentagr.htm kids-20220331.xsd kids-20220331_cal.xml kids-20220331_def.xml kids-20220331_lab.xml kids-20220331_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kids-20220331.htm": { "axisCustom": 0, "axisStandard": 29, "contextCount": 168, "dts": { "calculationLink": { "local": [ "kids-20220331_cal.xml" ] }, "definitionLink": { "local": [ "kids-20220331_def.xml" ] }, "inline": { "local": [ "kids-20220331.htm" ] }, "labelLink": { "local": [ "kids-20220331_lab.xml" ] }, "presentationLink": { "local": [ "kids-20220331_pre.xml" ] }, "schema": { "local": [ "kids-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 425, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 4, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 9 }, "keyCustom": 20, "keyStandard": 216, "memberCustom": 18, "memberStandard": 42, "nsprefix": "kids", "nsuri": "http://www.orthopediatrics.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.orthopediatrics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113103 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118104 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124105 - Disclosure - DEBT AND CREDIT ARRANGEMENTS", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS", "shortName": "DEBT AND CREDIT ARRANGEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128106 - Disclosure - INCOME TAXES", "role": "http://www.orthopediatrics.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130107 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134108 - Disclosure - NET LOSS PER SHARE", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARE", "shortName": "NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138109 - Disclosure - BUSINESS SEGMENT", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENT", "shortName": "BUSINESS SEGMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143110 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145111 - Disclosure - EMPLOYEE BENEFIT PLAN", "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147112 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149113 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTS", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314302 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325304 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables", "shortName": "DEBT AND CREDIT ARRANGEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331305 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335306 - Disclosure - NET LOSS PER SHARE (Tables)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables", "shortName": "NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339307 - Disclosure - BUSINESS SEGMENT (Tables)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables", "shortName": "BUSINESS SEGMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:CumulativeChildrenImpactedCount", "reportCount": 1, "unique": true, "unitRef": "children", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - BUSINESS (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSDetails", "shortName": "BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:CumulativeChildrenImpactedCount", "reportCount": 1, "unique": true, "unitRef": "children", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i52bca2495f4e443c96cc294ba018cd33_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EscrowDeposit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i52bca2495f4e443c96cc294ba018cd33_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EscrowDeposit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i7a8bd41d977940a1ac73f1161c80d504_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i7a8bd41d977940a1ac73f1161c80d504_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411407 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412408 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i496a4e056d344d96b6a9c0df5676c4e9_D20220101-20220331", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i3b3318b8a2824436a57138b8a2bf9241_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417411 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i62bd2bddce1846269beffc59e7838992_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i8117c18e27334ea8929af49bfc21b652_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420412 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i8117c18e27334ea8929af49bfc21b652_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421413 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ibd76c6c7682547c298a55d101a3d0eea_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422414 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ibd76c6c7682547c298a55d101a3d0eea_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ief6dc632e39540ff8e2e44fd60659a34_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "kids:ContingentConsiderationMeasurementInputPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423415 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ief6dc632e39540ff8e2e44fd60659a34_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "kids:ContingentConsiderationMeasurementInputPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i3f55ed016013425dbc9b4d011cc833e7_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426416 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i3f55ed016013425dbc9b4d011cc833e7_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeExpenseNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427417 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i3f55ed016013425dbc9b4d011cc833e7_I20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429418 - Disclosure - INCOME TAXES (Details)", "role": "http://www.orthopediatrics.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432419 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ie1eb5dcacf7b4a6198fd6157640d4cd3_I20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433420 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i496a4e056d344d96b6a9c0df5676c4e9_D20220101-20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436421 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails", "shortName": "NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437422 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "shortName": "NET LOSS PER SHARE - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440423 - Disclosure - BUSINESS SEGMENT - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails", "shortName": "BUSINESS SEGMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441424 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "iec0f19592f43485da0b19812f9e49359_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442425 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i6c931b0586834dd9b662f397971a26e7_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i2d357c9806f34740bf7182c58cc15d65_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "kids:NumberOfRelatedPartyEntitiesSuppliers", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444426 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i2d357c9806f34740bf7182c58cc15d65_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "kids:NumberOfRelatedPartyEntitiesSuppliers", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446427 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "shortName": "EMPLOYEE BENEFIT PLAN - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448428 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib41d072f22b64f6691188238b91a9bae_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450429 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib886ab2172994d7aa3f48be3e007b360_D20220401-20220401", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i5bbdc14c68bf4526840df4db38a08f7e_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "i5bbdc14c68bf4526840df4db38a08f7e_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - BUSINESS", "role": "http://www.orthopediatrics.com/role/BUSINESS", "shortName": "BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220331.htm", "contextRef": "ib0fdf55259bd40bdb1e1894731392544_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of Each Class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "kids_A2007EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2007 Equity Incentive Plan [Member]", "terseLabel": "2007 Plan" } } }, "localname": "A2007EquityIncentivePlanMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "kids_ApiFixLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ApiFix Ltd.", "label": "ApiFix Ltd. [Member]", "terseLabel": "ApiFix Ltd" } } }, "localname": "ApiFixLtdMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Noncurrent, Excluding Property, Plant and Equipment", "label": "Assets, Noncurrent, Excluding Property, Plant and Equipment", "totalLabel": "Total other assets" } } }, "localname": "AssetsNoncurrentExcludingPropertyPlantAndEquipment", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Current", "label": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Current", "verboseLabel": "Current portion of acquisition installment payable" } } }, "localname": "BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent", "label": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent", "verboseLabel": "Acquisition installment payable, net of current portion" } } }, "localname": "BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable", "label": "Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable", "terseLabel": "Acquisition installment payable" } } }, "localname": "BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "kids_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration Liability", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration Liability" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "domainItemType" }, "kids_ContingentConsiderationMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration, Measurement Input", "label": "Contingent Consideration, Measurement Input", "terseLabel": "Contingent consideration, measurement input" } } }, "localname": "ContingentConsiderationMeasurementInput", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "kids_ContingentConsiderationMeasurementInputPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration, Measurement Input, Period", "label": "Contingent Consideration, Measurement Input, Period", "terseLabel": "Expected years" } } }, "localname": "ContingentConsiderationMeasurementInputPeriod", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "durationItemType" }, "kids_CumulativeChildrenImpactedCount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Children Impacted, Count", "label": "Cumulative Children Impacted, Count", "terseLabel": "Impacted children" } } }, "localname": "CumulativeChildrenImpactedCount", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "kids_EmergingGrowthCompanyAndSmallerReportingCompanyReportingRequirementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy", "label": "Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy [Policy Text Block]", "terseLabel": "\"Emerging Growth Company\" and \"Smaller Reporting Company\" Reporting Requirements" } } }, "localname": "EmergingGrowthCompanyAndSmallerReportingCompanyReportingRequirementsPolicyPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_EstimatedMarketPortionOpportunities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated Market Portion Opportunities", "label": "Estimated Market Portion Opportunities", "terseLabel": "Estimated market portion opportunities" } } }, "localname": "EstimatedMarketPortionOpportunities", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails" ], "xbrltype": "monetaryItemType" }, "kids_FiniteLivedIntangibleAssetUsefulLifeExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Useful Life Extension Period", "label": "Finite-Lived Intangible Asset, Useful Life Extension Period", "terseLabel": "Finite lived intangible asset useful life extension period (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLifeExtensionPeriod", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "kids_FireflyTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Firefly Technology", "label": "Firefly Technology [Member]", "terseLabel": "Firefly Technology" } } }, "localname": "FireflyTechnologyMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "kids_IncreaseDecreaseInSettlementLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Settlement Liabilities, Current", "label": "Increase (Decrease) In Settlement Liabilities, Current", "negatedTerseLabel": "Accrued legal settlements" } } }, "localname": "IncreaseDecreaseInSettlementLiabilitiesCurrent", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "kids_LongTermDebtCurrentMaturitiesRelatedParty": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Current Maturities, Related Party", "label": "Long-term Debt, Current Maturities, Related Party", "terseLabel": "Current portion of long-term debt with affiliate" } } }, "localname": "LongTermDebtCurrentMaturitiesRelatedParty", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_MitchellDesignsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mitchell Designs, Inc", "label": "Mitchell Designs, Inc [Member]", "terseLabel": "Mitchell Designs, Inc" } } }, "localname": "MitchellDesignsIncMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "kids_New2017EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New 2017 Equity Incentive Plan [Member]", "terseLabel": "2017 Plan" } } }, "localname": "New2017EquityIncentivePlanMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "kids_NumberOfRelatedPartyEntitiesSuppliers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Related Party Entities Suppliers", "label": "Number Of Related Party Entities Suppliers", "terseLabel": "Number of related party suppliers" } } }, "localname": "NumberOfRelatedPartyEntitiesSuppliers", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "integerItemType" }, "kids_OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation", "label": "Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation", "terseLabel": "Estimated limitation on losses generated prior to ownership change date" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation Annual Limit", "terseLabel": "Estimated annual limitation of losses" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards Limitations On Use Estimated Amount Subject to Limitation Annual Limit Increase", "terseLabel": "Increase of estimated annual limitation of first five years" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyAgreementPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement Contract to Perform for Others Royalty Agreement Percent", "terseLabel": "Royalty agreement percentage (as a percent)" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyAgreementPercent", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "percentItemType" }, "kids_SalesAndMarketingExpensePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales And Marketing Expense Policy [Policy Text Block]", "terseLabel": "Sales and Marketing Expenses" } } }, "localname": "SalesAndMarketingExpensePolicyPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_SampleInventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sample Inventory [Member]", "terseLabel": "Sample inventory" } } }, "localname": "SampleInventoryMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "kids_SecondAmendedLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amended Loan Agreement", "label": "Second Amended Loan Agreement [Member]", "terseLabel": "Second Amended Loan Agreement" } } }, "localname": "SecondAmendedLoanAgreementMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "kids_SecuredOvernightFinancingRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate", "label": "Secured Overnight Financing Rate [Member]", "terseLabel": "Secured Overnight Financing Rate" } } }, "localname": "SecuredOvernightFinancingRateMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "kids_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercisable Number", "terseLabel": "Restricted stock exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "kids_SpineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spine [Member]", "label": "Spine [Member]", "terseLabel": "Scoliosis" } } }, "localname": "SpineMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_SportsMedicineAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sports Medicine And Other [Member]", "label": "Sports Medicine And Other [Member]", "terseLabel": "Sports medicine/other" } } }, "localname": "SportsMedicineAndOtherMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_SquadronMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Squadron", "label": "Squadron [Member]", "terseLabel": "Squadron" } } }, "localname": "SquadronMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "kids_StructureMedicalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure Medical, LLC", "label": "Structure Medical, LLC [Member]", "terseLabel": "Structure Medical, LLC" } } }, "localname": "StructureMedicalLLCMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "kids_TeamNoteBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Team Note B", "label": "Team Note B [Member]", "terseLabel": "Team note B" } } }, "localname": "TeamNoteBMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "kids_ThirdAmendedLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Amended Loan Agreement", "label": "Third Amended Loan Agreement [Member]", "terseLabel": "Third Amended Loan Agreement" } } }, "localname": "ThirdAmendedLoanAgreementMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "kids_TransferOfPropertyAndEquipmentToInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Transfer Of Property And Equipment To Inventory", "terseLabel": "Transfer of instruments from property and equipment to inventory" } } }, "localname": "TransferOfPropertyAndEquipmentToInventory", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "kids_TraumaAndDeformityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trauma and Deformity [Member]", "terseLabel": "Trauma and deformity" } } }, "localname": "TraumaAndDeformityMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_VilexAndOrthexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vilex and Orthex", "label": "Vilex and Orthex [Member]", "terseLabel": "Vilex and Orthex" } } }, "localname": "VilexAndOrthexMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "kids_VilexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vilex", "label": "Vilex [Member]", "terseLabel": "Vilex" } } }, "localname": "VilexMember", "nsuri": "http://www.orthopediatrics.com/20220331", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r315", "r450", "r451", "r453", "r575" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r53", "r55", "r108", "r109", "r252", "r283" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r251", "r282", "r326", "r328", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r548", "r551", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r251", "r282", "r326", "r328", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r548", "r551", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r173", "r300", "r301", "r498", "r547", "r549" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r173", "r300", "r301", "r498", "r547", "r549" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r251", "r282", "r305", "r326", "r328", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r548", "r551", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r251", "r282", "r305", "r326", "r328", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r548", "r551", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r54", "r55", "r108", "r109", "r252", "r283" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r174", "r175", "r300", "r302", "r550", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r174", "r175", "r300", "r302", "r550", "r560", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable - trade" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r7", "r27", "r179", "r180" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable - trade, less allowance for doubtful accounts of $357 and $347, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r57", "r58", "r59", "r538", "r556", "r557" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r67", "r68", "r69", "r112", "r113", "r114", "r409", "r552", "r553", "r593" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r357", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r112", "r113", "r114", "r354", "r355", "r356", "r414" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r331", "r350", "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r34", "r185", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r190", "r306" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset Backed Securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r104", "r157", "r162", "r169", "r196", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r406", "r410", "r430", "r456", "r458", "r515", "r535" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r52", "r104", "r196", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r406", "r410", "r430", "r456", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r332", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and building improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r325", "r327", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Issuance of common stock" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Consideration for acquisition (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Common stock (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r394", "r395", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r92", "r402" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Fair value adjustment of contingent consideration", "verboseLabel": "Fair value adjustment of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r393", "r396", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent Consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r393", "r397" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisition Payable and Contingent Consideration" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r37", "r95" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r16", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents and Short Term Investments" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r89", "r95", "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and restricted cash, end of period", "periodStartLabel": "Cash and restricted cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r89", "r431" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET (DECREASE) INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r229", "r230", "r231", "r232", "r561" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r233", "r563" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Litigation and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r112", "r113", "r414" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r285" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00025 par value; 50,000,000 shares authorized; 19,821,298 shares and 19,677,214 shares issued as of March\u00a031, 2022 (unaudited) and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r62", "r64", "r65", "r73", "r525", "r543" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r306", "r321", "r558" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r78", "r498" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r102", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r265", "r272", "r273", "r275", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT AND CREDIT ARRANGEMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r103", "r110", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r261", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r277", "r278", "r279", "r280", "r442", "r516", "r517", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate (as a percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r46", "r249" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r47", "r103", "r110", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r261", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r277", "r278", "r279", "r280", "r442" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r47", "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly interest and principal installments" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r47", "r103", "r110", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r261", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r274", "r277", "r278", "r279", "r280", "r286", "r287", "r288", "r289", "r440", "r441", "r442", "r443", "r532" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r364", "r365" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer contribution as a percentage of employees' salary (as a percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r93", "r155" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Divestiture purchase price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal and state" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r74", "r117", "r118", "r119", "r120", "r121", "r125", "r127", "r129", "r130", "r131", "r135", "r136", "r415", "r416", "r526", "r544" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r74", "r117", "r118", "r119", "r120", "r121", "r127", "r129", "r130", "r131", "r135", "r136", "r415", "r416", "r526", "r544" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r132", "r133", "r134", "r137" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r431" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense, weighted average period of recognition (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock option", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r67", "r68", "r69", "r112", "r113", "r114", "r116", "r122", "r124", "r139", "r197", "r285", "r290", "r354", "r355", "r356", "r377", "r378", "r414", "r432", "r433", "r434", "r435", "r436", "r437", "r552", "r553", "r554", "r593" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r522", "r562" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r417", "r418", "r419", "r426" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of fair value measurement inputs and valuation techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r263", "r277", "r278", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r321", "r418", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r417", "r418", "r421", "r422", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r263", "r306", "r308", "r313", "r321", "r418", "r465" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r263", "r277", "r278", "r306", "r308", "r313", "r321", "r418", "r466" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r263", "r277", "r278", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r321", "r418", "r467" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r423", "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of fair value, liabilities measured on recurring basis, unobservable input reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Contingent consideration, ending balance", "periodStartLabel": "Contingent consideration, beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r263", "r277", "r278", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r321", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r425", "r427" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r190", "r191", "r193", "r194", "r195", "r199", "r200", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r274", "r284", "r413", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r584", "r585", "r586", "r587", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "verboseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r222" ], "calculation": { "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r217", "r219", "r222", "r224", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r222", "r500" ], "calculation": { "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r217", "r221" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r222", "r499" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0 }, "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Amortizable intangible assets, net", "totalLabel": "Net Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted-Average Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r212", "r213", "r458", "r514" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r215", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation impact" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r77", "r104", "r157", "r161", "r165", "r168", "r171", "r196", "r235", "r236", "r237", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r430" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r93", "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment charges, indefinite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r93", "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of indefinitely-lived tradename assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r157", "r161", "r165", "r168", "r171", "r513", "r523", "r528", "r545" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r105", "r368", "r371", "r374", "r379", "r381", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Examination" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r123", "r124", "r156", "r366", "r380", "r382", "r546" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "terseLabel": "Provision for income taxes (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r66", "r362", "r363", "r371", "r372", "r373", "r376" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans.", "label": "Increase (Decrease) in Accounts and Notes Receivable", "negatedTerseLabel": "Accounts receivable - trade" } } }, "localname": "IncreaseDecreaseInAccountsAndNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable - trade" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in certain current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r218", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r223" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Other intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r218", "r223" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r99", "r221", "r495", "r496", "r497", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Amortizable Intangible Assets, net" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Intellectual Property" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r527" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r88", "r90", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r50", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r51", "r100", "r138", "r209", "r210", "r211", "r493" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories, net" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Short term investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r104", "r163", "r196", "r235", "r236", "r237", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r407", "r410", "r411", "r430", "r456", "r457" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r104", "r196", "r430", "r458", "r519", "r540" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r104", "r196", "r235", "r236", "r237", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r407", "r410", "r411", "r430", "r456", "r457", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r13", "r14", "r15", "r22", "r23", "r104", "r196", "r235", "r236", "r237", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r407", "r410", "r411", "r430", "r456", "r457" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "License Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Unused commitment fee percentage (as a percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Revolving credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Legal settlement expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "Three month LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r262", "r276", "r277", "r278", "r517", "r536" ], "calculation": { "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt with affiliate", "verboseLabel": "Less: current maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt with affiliate, net of current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesAndLoans": { "auth_ref": [ "r47" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes and Loans, Noncurrent", "terseLabel": "Long-term debt with affiliate, net of current portion" } } }, "localname": "LongTermNotesAndLoans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r47", "r234" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Present value discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility factor" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgage payable to affiliate" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r140", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r89", "r91", "r94" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r60", "r63", "r69", "r72", "r94", "r104", "r115", "r117", "r118", "r119", "r120", "r123", "r124", "r128", "r157", "r161", "r165", "r168", "r171", "r196", "r235", "r236", "r237", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r416", "r430", "r524", "r542" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Note payable to Squadron" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of Reporting Units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office and other equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r157", "r161", "r165", "r168", "r171" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r4", "r111", "r148", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other assets:" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r404", "r405", "r408" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized loss on short-term investments" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r404", "r405", "r408" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r61", "r64", "r404", "r405", "r408" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss", "totalLabel": "Other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r192", "r204", "r306", "r425" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r44", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expenses:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r84", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "verboseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r85" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of licenses" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r85" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r305", "r307", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r329" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLAN" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r332", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r35", "r36" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r82", "r83", "r189" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Sale of short-term marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r86", "r353" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r39", "r228" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r228", "r458", "r530", "r541" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r38", "r228", "r564", "r565" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and equipment, depreciable lives" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r227" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Depreciable lives (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r24", "r518", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Purchase commitment, remaining minimum amount committed" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r315", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r315", "r450", "r451", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Payments to related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r315", "r450", "r453", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r448", "r449", "r451", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r87" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Payments on mortgage notes" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "terseLabel": "Payments on note with affiliate" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r361", "r494", "r578" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r5", "r16", "r98" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r290", "r357", "r458", "r539", "r555", "r557" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r112", "r113", "r114", "r116", "r122", "r124", "r197", "r354", "r355", "r356", "r377", "r378", "r414", "r552", "r554" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r153", "r154", "r160", "r166", "r167", "r173", "r174", "r177", "r299", "r300", "r498" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r101", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition - United States and International" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r75", "r238", "r240", "r241", "r245", "r246", "r247", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Sales to related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r47", "r110", "r277", "r279", "r286", "r287", "r288", "r289", "r440", "r441", "r443", "r532" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schdule of reconciliation of basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value, assets and liabilities measured on recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r217", "r221", "r499" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r217", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r39", "r228" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r76", "r176" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of product sales by geographic location" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r70", "r176" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r157", "r158", "r164", "r215" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r157", "r158", "r164", "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of product sales by category" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r332", "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r338", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r149", "r151", "r152", "r157", "r159", "r165", "r169", "r170", "r171", "r172", "r173", "r176", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "BUSINESS SEGMENT" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at period end (in shares)", "periodStartLabel": "Outstanding at period start (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-average remaining contractual terms (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares available for award (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options, granted (in shares)", "verboseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r340", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at period end (in shares)", "periodStartLabel": "Outstanding at period start (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at period end, weighted-average exercise price (in dollars per share)", "periodStartLabel": "Outstanding at period start, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r330", "r335" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Vesting period one" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Vesting period two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r332", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Contractual terms (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r20", "r520", "r521", "r534" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Business software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r49", "r67", "r68", "r69", "r112", "r113", "r114", "r116", "r122", "r124", "r139", "r197", "r285", "r290", "r354", "r355", "r356", "r377", "r378", "r414", "r432", "r433", "r434", "r435", "r436", "r437", "r552", "r553", "r554", "r593" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r112", "r113", "r114", "r139", "r498" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r25", "r26", "r285", "r290" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r285", "r290", "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Stock option exercise (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r285", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r49", "r285", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercise" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r104", "r187", "r196", "r430", "r458" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r438", "r460" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r438", "r460" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r438", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r438", "r460" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r459", "r461" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.", "label": "Technology Equipment [Member]", "terseLabel": "Instruments" } } }, "localname": "TechnologyEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r181", "r182", "r183", "r184", "r186", "r188" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r190", "r191", "r193", "r194", "r195", "r274", "r284", "r413", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r584", "r585", "r586", "r587", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "verboseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r107", "r306", "r321", "r529" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "Treasury Bonds" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r141", "r142", "r143", "r144", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Discounted cash flow, Monte Carlo" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r126", "r131" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common stock - diluted (in shares)", "verboseLabel": "Weighted average number of shares - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r125", "r131" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common stock - basic (in shares)", "verboseLabel": "Weighted average number of shares - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r359": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r439": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r455": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r461": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r579": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r580": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r581": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r582": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r583": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r584": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r585": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r586": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r587": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r588": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r589": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r590": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r591": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r592": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 79 0001425450-22-000051-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001425450-22-000051-xbrl.zip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end

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